<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Guillain-Barré syndrome in adults: Pathogenesis, clinical features, and diagnosis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Guillain-Barré syndrome in adults: Pathogenesis, clinical features, and diagnosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Guillain-Barré syndrome in adults: Pathogenesis, clinical features, and diagnosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Swathy Chandrashekhar, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mazen M Dimachkie, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeremy M Shefner, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alejandro A Rabinstein, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard P Goddeau, Jr, DO, FAHA</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 27, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The acute immune-mediated polyneuropathies are classified under the eponym Guillain-Barré syndrome (GBS) after some of the authors of early descriptions of the disease. GBS is one of the most common causes of acute, acquired weakness and is often provoked by a preceding infection. GBS may be complicated in some cases by respiratory failure or autonomic dysfunction.</p><p>The pathogenesis, clinical features, and diagnosis of GBS will be discussed here. Other aspects of GBS are presented separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5172.html" rel="external">"Guillain-Barré syndrome in adults: Treatment and prognosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6235.html" rel="external">"Guillain-Barré syndrome in children: Epidemiology, clinical features, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6204.html" rel="external">"Guillain-Barré syndrome in children: Treatment and prognosis"</a>.)</p><p></p><p class="headingAnchor" id="H1609001756"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>The acute polyneuropathy of GBS is often triggered when an immune response to an antecedent infection or other event cross-reacts with shared epitopes on peripheral nerve (molecular mimicry) [<a href="#rid1">1,2</a>]. All myelinated nerves (motor, sensory, cranial, sympathetic) can be affected.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathology</strong> – The range and extent of pathologic changes depend on the clinical forms of GBS. Patients with the common acute inflammatory demyelinating polyneuropathy (AIDP) form have prominent demyelination on electrodiagnostic studies and lymphocytic infiltration on sural nerve biopsies, while those with other forms such as acute motor axonal neuropathy (AMAN) form have prominent axonal loss without lymphocytic infiltration or complement activation and few degenerating nerve fibers [<a href="#rid3">3</a>]. (See <a class="local">'Variant forms of Guillain-Barré syndrome'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Demyelination</strong> – In AIDP and the Miller Fisher syndrome (MFS) variant form, a focal inflammatory response develops against myelin-producing Schwann cells or peripheral myelin [<a href="#rid4">4-6</a>]. Demyelination is thought to start at the level of the nerve roots where the blood-nerve barrier is deficient. The breakdown of the blood-nerve barrier at the dural attachment allows transudation of plasma proteins into the cerebrospinal fluid. Infiltration of the epineurial and endoneurial small vessels (mostly veins) by activated T cells is followed by macrophage-mediated demyelination with evidence of complement and immunoglobulin deposition on myelin and Schwann cells [<a href="#rid5">5,7,8</a>].</p><p></p><p class="bulletIndent2">Demyelination blocks electrical saltatory conduction along the nerve. This causes conduction slowing and leads to muscle weakness. More widespread but patchy peripheral nerve demyelination follows, with added electrical conduction block causing further weakness and electrophysiologic evidence of nonuniform conduction slowing within and across different nerves. Axonal degeneration occurs as a secondary bystander response; the extent relates to the intensity of the inflammatory response.</p><p></p><p class="bulletIndent2">Peripheral nerve remyelination occurs in recovery over several weeks to months. However, in a small percentage of patients, there is superimposed severe axonal degeneration with markedly delayed and incomplete recovery.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Axonal loss</strong> – Immune reactions against epitopes in the axonal membrane cause the acute axonal forms of GBS: AMAN and acute motor and sensory axonal neuropathy (AMSAN) [<a href="#rid4">4</a>]. These forms are relatively uncommon in the United States but more frequent presentations of GBS in Asia. (See <a class="local">'Acute axonal neuropathies'</a> below.)</p><p></p><p class="bulletIndent2">In the axonal variants of GBS, antibody and complement-mediated humoral immune response leads to direct axolemma injury [<a href="#rid9">9,10</a>]. There is a paucity of inflammatory infiltration. The primary immune process is directed at the nodes of Ranvier (short intervals between successive segments of the myelin sheath along a nerve), leading to axonal involvement with conduction block caused by paranodal myelin detachment, node lengthening, sodium channel dysfunction, and altered ion and water homeostasis [<a href="#rid11">11</a>]. This process can rapidly reverse in some cases but may progress to axonal degeneration in others. The motor nerves are involved at the ventral roots, peripheral nerve, and the preterminal intramuscular motor twigs [<a href="#rid12">12</a>]. In the motor-sensory variant, sensory nerves also are affected.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Autoantibodies and molecular mimicry</strong> – GBS is triggered by a cross-reaction of an immune response to an antecedent infection or other event with shared epitopes on peripheral nerve (molecular mimicry). Autoantibodies that react with epitopes on peripheral nerve appear to be the immune trigger after an acute infection in many cases of GBS [<a href="#rid1">1,2,13-15</a>].</p><p></p><p class="bulletIndent1">A case report from Japan in 1990 linking AMAN to a preceding infection with <em>Campylobacter jejuni </em>and antibodies to the GM1 monosialoganglioside prompted interest in the role of <em>Campylobacter </em>and antiganglioside antibodies in GBS [<a href="#rid16">16-18</a>]. Subsequent reports on <em>C. jejuni</em> have provided further insight into the mechanistic role of autoantibodies in the development of GBS through molecular mimicry [<a href="#rid19">19</a>].</p><p></p><p class="bulletIndent1">Infection with <em>C. jejuni</em> is the most common antecedent in GBS and a leading cause of acute gastroenteritis [<a href="#rid20">20</a>]. (See <a class="local">'Infection'</a> below.)</p><p></p><p class="bulletIndent1"><em>C. jejuni </em>can generate antibodies to specific gangliosides, including GM1, GD1a, GalNac-GD1a, and GD1b, which are strongly associated with AMAN and AMSAN [<a href="#rid21">21</a>]. A strain of C. jejuni isolated from an AMAN patient carrying immunoglobulin (Ig)G anti-GM1 antibody expressed an oligosaccharide structure identical to that of the terminal tetrasaccharide of the GM1 ganglioside [<a href="#rid22">22</a>]. Autopsy studies show that, in AMAN, IgG is deposited on the axolemma of the spinal anterior root [<a href="#rid21">21</a>], indicating that IgG is an important factor in the development of AMAN [<a href="#rid9">9</a>]. (See <a class="local">'Acute axonal neuropathies'</a> below.)</p><p></p><p class="bulletIndent1">Similarly, <em>C. jejuni</em> infection can generate antibodies to the GQ1b ganglioside, a component of oculomotor nerve myelin [<a href="#rid23">23</a>]. GQ1b antibodies are frequently found in variants characterized by ophthalmoplegia, such as MFS and Bickerstaff brainstem encephalitis (BBE) [<a href="#rid23">23,24</a>]. Antibodies to GT1a, which cross-react with GQ1b, have also been associated with bulbar forms of GBS [<a href="#rid25">25,26</a>]. (See <a class="local">'GQ1b syndromes'</a> below and <a class="local">'Rare variants'</a> below.)</p><p></p><p class="bulletIndent1">Patients with <em>C. jejuni</em> enteritis not complicated by GBS do not produce the specific antiganglioside antibodies [<a href="#rid17">17</a>]. Genetic polymorphisms in lipooligosaccharide biosynthesis genes in <em>C. jejuni</em> that modify ganglioside expression as well as immunogenetic factors in the host are thought to play a role in the development of GBS [<a href="#rid27">27</a>].</p><p></p><p class="bulletIndent1">There is also an association between GBS and infection with <em>Haemophilus influenzae, Mycoplasma pneumoniae</em>, and cytomegalovirus. Cytomegalovirus infections were associated with antibodies to the ganglioside GM2 and with severe motor and sensory deficits. Other infections were not related to specific antiganglioside antibodies and neurologic patterns in GBS, but these relationships are not well documented [<a href="#rid12">12,22</a>].</p><p></p><p class="bulletIndent1">These antiganglioside antibodies are considered to be the pathogenic components that trigger GBS because of their association with the acute illness in GBS and because immune-mediated therapies such as plasma exchange are effective treatments for GBS [<a href="#rid28">28</a>]. (See  <a class="medical medical_review" href="/z/d/html/5172.html" rel="external">"Guillain-Barré syndrome in adults: Treatment and prognosis", section on 'Immunomodulatory therapy'</a>.)</p><p></p><p class="headingAnchor" id="H1625733692"><span class="h1">ANTECEDENT EVENTS</span><span class="headingEndMark"> — </span>In some studies, up to two-thirds of patients give a history of an antecedent respiratory tract or gastrointestinal infection [<a href="#rid10">10,29,30</a>]. In the International Guillain Barré Syndrome Outcome Study (IGOS), 76 percent of patients reported a triggering event in the four weeks prior to GBS [<a href="#rid31">31</a>]. This included an upper respiratory tract infection in 35 percent and gastroenteritis in 27 percent.</p><p class="headingAnchor" id="H2546552464"><span class="h2">Infection</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>Campylobacter jejuni</em></strong><strong> infection</strong> – <em>C. jejuni</em> gastroenteritis is the most common precipitant of GBS, identified in approximately 25 percent of cases [<a href="#rid20">20,32</a>]. Of note, only 70 percent of those infected with <em>C. jejuni</em> reported a diarrheal illness within 12 weeks before GBS onset. In an analysis of available biosamples from 768 patients in the IGOS cohort, laboratory evidence of recent <em>C. jejuni</em> infection was found in 30 percent [<a href="#rid30">30</a>].</p><p></p><p class="bulletIndent1">A study from Sweden estimated that the risk for developing GBS during the two months following a symptomatic episode of <em>C. jejuni</em> infection was approximately 100-fold higher than the risk in the general population, with GBS developing in an estimated 0.03 percent of patients with <em>C. jejuni</em> enteritis [<a href="#rid33">33</a>].</p><p></p><p class="bulletIndent1">There are significant geographical differences in <em>C. jejuni</em> infection. Certain strains of <em>C. jejuni</em> have been associated with GBS in Japan (strain O-19) and South Africa (strain O-41) but not in Europe [<a href="#rid34">34,35</a>]. Likewise, the rate of preceding <em>C. jejuni</em> infection varies by the form of GBS, being found in about 60 to 70 percent of acute motor axonal neuropathy (AMAN) and acute motor and sensory axonal neuropathy (AMSAN) cases and up to 30 percent of acute inflammatory demyelinating polyneuropathy (AIDP) cases [<a href="#rid36">36,37</a>].</p><p></p><p class="bulletIndent1">Furthermore, <em>Campylobacter</em>-associated GBS appears to have a worse prognosis than patients with other triggers, manifested by slower recovery and greater residual neurologic disability [<a href="#rid20">20</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other infections</strong> – Multiple reports have found an increased risk of GBS following other influenza-like illnesses [<a href="#rid29">29,38-41</a>]. In one study from the United Kingdom, the relative risk of GBS within 90 days after an influenza-like illness was 7.4 (95% CI 4.4-12.4) [<a href="#rid38">38</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cytomegalovirus</strong> – Antecedent cytomegalovirus infections have also been associated with GBS [<a href="#rid42">42-44</a>]. As an example, a case-control study from the Netherlands that evaluated 308 patients found that serologic evidence of recent infections, including cytomegalovirus, was significantly more common among patients who developed GBS than matched-control patients who had other neurologic diseases [<a href="#rid45">45</a>]. Patients with human immunodeficiency virus (HIV) infection were excluded from this series. Laboratory evidence of recent cytomegalovirus infection was found in 30 of 768 patients (4 percent) in the IGOS cohort [<a href="#rid30">30</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Influenza A and B</strong> – In a study of 150 patients with GBS from China, influenza A and B were the most common antecedent infections after <em>C. jejuni</em>, accounting for 17 and 16 percent, respectively. Influenza B has been associated with a pure motor form of GBS that more frequently requires mechanical ventilation compared with influenza A, which is usually less severe [<a href="#rid32">32,46</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>HIV</strong> – GBS also occurs in association with HIV infection, predominantly in those who are not immunocompromised. However, GBS can occur in any stage of HIV infection [<a href="#rid47">47</a>]. GBS has been reported after acute HIV seroconversion and following immune reconstitution from highly active antiretroviral therapy [<a href="#rid48">48</a>]. The clinical course and prognosis of GBS in patients with HIV infection appears similar to GBS in those without HIV infection.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>COVID-19 virus</strong> – Several cases of para- and post-infectious GBS associated with coronavirus disease 2019 (COVID-19) have been reported, though a direct causal relationship has not been established [<a href="#rid49">49-51</a>]. In a case-control study of 76 patients with GBS occurring over an 18-month period during 2021 and 2022, COVID-19 infection occurred in 11.8 percent of patients within six weeks prior to GBS compared with 2.4 percent of matched controls without GBS [<a href="#rid52">52</a>]. GBS associated with COVID-19 infection appears similar to classic GBS in clinical presentation, electrodiagnostic evaluation, and response to treatment [<a href="#rid53">53,54</a>]. (See  <a class="medical medical_review" href="/z/d/html/128153.html" rel="external">"COVID-19: Neurologic complications and management of neurologic conditions", section on 'Guillain-Barré syndrome'</a>.)</p><p></p><p class="bulletIndent2">The risk of GBS appears higher with COVID-19 infection than with COVID-19 vaccination [<a href="#rid52">52</a>]. The association between GBS and vaccinations against COVID-19 are presented separately. (See <a class="local">'Vaccinations'</a> below and  <a class="medical medical_review" href="/z/d/html/129849.html" rel="external">"COVID-19: Vaccines", section on 'Guillain-Barré syndrome'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Zika virus</strong> – An association between Zika virus infection and GBS has been reported, but a direct causal relationship has not been firmly established. This issue is discussed in greater detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/106169.html" rel="external">"Zika virus infection: An overview", section on 'Guillain-Barré syndrome'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Others</strong> – GBS has been reported following infection with the varicella-zoster virus, Epstein-Barr virus, herpes simplex virus, hepatitis E, chikungunya virus, Japanese encephalitis virus, and the bacteria <em>H. influenzae</em>, <em>Escherichia coli</em>, and <em>M. pneumoniae</em> [<a href="#rid30">30,45,55-60</a>]. Approximately 6 percent of patients from the IGOS cohort were found to have laboratory evidence of multiple recent antecedent infections [<a href="#rid30">30</a>]. The importance of these infectious agents as triggers of GBS is uncertain.</p><p></p><p class="headingAnchor" id="H994917382"><span class="h2">Vaccinations</span><span class="headingEndMark"> — </span>Some instances of GBS have followed vaccination, but the associated risks appear small or negligible. Some studies have failed to find an association between vaccination and subsequent GBS risk. As an example, individuals who received either the 1992-1993 or 1993-1994 influenza vaccinations were not at significantly increased risk for GBS, but combining the two seasons suggested that influenza vaccination resulted in approximately one additional case of GBS per million patients inoculated [<a href="#rid61">61</a>]. By contrast, a retrospective study that analyzed a northern California health care database from 1994 through 2006 found no increased risk of incident GBS following any vaccination and all vaccinations combined, whether using a 6-week or 10-week risk interval [<a href="#rid62">62</a>].</p><p>There appears to be little or no risk of GBS associated with routine immunization schedules. In a study that analyzed a large database of 253 general practices in the United Kingdom with a mean of 1.8 million registered patients from 1992 to 2000, there were 228 incident cases of GBS [<a href="#rid63">63</a>]. Onset of GBS within 42 days of any immunization occurred in seven patients (3.1 percent), with an adjusted relative risk of 1.03 (95% CI 0.48-2.18).</p><p>The risk of GBS after vaccination appears substantially lower than the risk of GBS triggered by acute infection [<a href="#rid64">64,65</a>]. In addition, preventing acute illness through vaccination can reduce infection-triggered GBS. Vaccination has not been associated with GBS recurrence [<a href="#rid66">66,67</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Influenza vaccination</strong> – In the United States, an increased risk of GBS was associated with the swine influenza vaccine in 1976, although the severity of the risk has been controversial [<a href="#rid29">29,41</a>]. Subsequent meta-analyses and cohort studies have found that influenza vaccination is associated with low or negligible risks of GBS and has supported the safety of vaccinations [<a href="#rid38">38,68-73</a>]. As examples, a meta-analysis of data from six adverse event monitoring systems, the 2009 H1N1 influenza A vaccine used in the United States was associated with a small increased risk of GBS (relative risk [RR] 2.35, 95% CI 1.42-4.01) [<a href="#rid68">68</a>]. The number of excess GBS cases was estimated to be 1.6 per 1 million people vaccinated. In a population-based cohort study from Quebec evaluating the H1N1 vaccination during the fall of 2009, a small but significantly increased risk of GBS was reported for the eight-week postvaccination period (adjusted RR 1.80, 95% CI 1.12-2.87) and during the four-week postvaccination period (RR 2.75, 95% CI 1.63-4.62) [<a href="#rid69">69</a>]. The number of excess GBS cases attributable to the vaccine was approximately 2 per 1 million doses [<a href="#rid38">38,39</a>].</p><p></p><p class="bulletIndent1">Other studies have failed to identify a risk of GBS associated with influenza vaccination [<a href="#rid38">38,70-72</a>]. In a multinational self-controlled case series in Europe, there was an elevated risk of GBS following influenza infection but not following influenza vaccination [<a href="#rid71">71</a>]. Moreover, when adjusted for confounding by influenza-like illnesses, there was no association of GBS with the pandemic H1N1 vaccine [<a href="#rid70">70-72</a>].</p><p></p><p class="bulletIndent1">A history of GBS should not be considered a strict contraindication for influenza vaccination, except for patients who had GBS over the preceding three months or had vaccination-related GBS [<a href="#rid67">67,74,75</a>]. The management of patients with GBS is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5172.html" rel="external">"Guillain-Barré syndrome in adults: Treatment and prognosis", section on 'Subsequent immunizations'</a>.)</p><p></p><p class="bulletIndent1">The risk of GBS associated with influenza vaccination, approximately one to two excess cases of GBS per million people vaccinated, is substantially less than the overall health risk posed by naturally occurring influenza [<a href="#rid41">41</a>]. Influenza vaccination for the prevention of seasonal influenza is reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/7007.html" rel="external">"Seasonal influenza vaccination in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Meningococcal vaccination</strong> – Cases of GBS have been reported following administration of the <a class="drug drug_general" data-topicid="10140" href="/z/d/drug information/10140.html" rel="external">quadrivalent meningococcal conjugate vaccine</a> MCV4 (Menactra). This issue, along with meningococcal vaccine recommendations, is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3901.html" rel="external">"Meningococcal vaccination in children and adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Recombinant zoster vaccination</strong> – Cases of GBS have been observed in a postmarketing observational study during the 42 days following vaccination [<a href="#rid76">76</a>]. These cases represent an increased risk of 3 cases per 1 million doses of vaccine administered to adults age 65 and older. (See  <a class="medical medical_review" href="/z/d/html/8343.html" rel="external">"Vaccination for the prevention of shingles (herpes zoster)", section on 'Adverse events'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>COVID-19 vaccination</strong> – Cases of GBS have been observed with the adenovirus vector-based Janssen/Johnson &amp; Johnson (Ad26.COV2.S) and AstraZeneca (ChAdOx1 nCoV-19/AZD1222) COVID-19 vaccines in the United States and Europe [<a href="#rid77">77-81</a>]. In the United States, 123 cases occurring within six weeks of immunization in 2021 were reported among 13.2 million administered doses [<a href="#rid81">81</a>]. Adenovirus vector vaccines for COVID-19 are no longer available in the United States. (See  <a class="medical medical_review" href="/z/d/html/129849.html" rel="external">"COVID-19: Vaccines"</a>.)</p><p></p><p class="bulletIndent1">Rare cases of GBS have been reported with messenger ribonucleic acid (mRNA)-based COVID-19 vaccines, however data from multiple population-based studies suggest this finding may reflect the baseline risk of GBS [<a href="#rid82">82-85</a>]. In one cohort of 76 patients with GBS occurring during an 18-month period of 2021 and 2022, receipt of an mRNA COVID-19 vaccine dose in the preceding six weeks was associated with a <strong>reduced</strong> risk of subsequent GBS (odds ratio 0.41, 95% CI 0.17-0.96) [<a href="#rid52">52</a>].</p><p></p><p>The US Food and Drug Administration (FDA) and United States Centers for Disease Control and Prevention (CDC) request that practitioners report possible cases of GBS occurring after vaccination to the Vaccine Adverse Events Reporting System (VAERS) online at <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fvaers.hhs.gov%2F&amp;token=8m3rK0tzv73hmwLVujPJP2ExUaq%2FDfXBz50uj1EPWpI%3D&amp;TOPIC_ID=5137" target="_blank">https://vaers.hhs.gov/</a> or by telephone at 800-822-7967.</p><p class="headingAnchor" id="H125747069"><span class="h2">Other triggers</span><span class="headingEndMark"> — </span>A small percentage of patients develop GBS after other triggering events such as surgery, trauma, or bone-marrow transplantation [<a href="#rid86">86,87</a>]. GBS has also been linked to systemic processes, including Hodgkin lymphoma, systemic lupus erythematosus, and sarcoidosis [<a href="#rid88">88</a>]. GBS does not appear to occur with increased frequency during pregnancy, but the incidence may be increased in the postpartum period [<a href="#rid89">89</a>]. Several medications have been reported to trigger GBS, including:</p><p class="bulletIndent1"><span class="glyph">●</span>Tumor necrosis factor-alpha antagonist therapy [<a href="#rid90">90</a>]</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">Tacrolimus</a> and <a class="drug drug_general" data-topicid="10291" href="/z/d/drug information/10291.html" rel="external">suramin</a> [<a href="#rid91">91</a>]</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">Isotretinoin</a> [<a href="#rid92">92</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Immune checkpoint inhibitors [<a href="#rid93">93-96</a>]</p><p></p><p class="headingAnchor" id="H284586891"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>GBS occurs worldwide with an overall incidence of 1 to 2 cases per 100,000 per year [<a href="#rid1">1,2,97,98</a>]. While all age groups are affected, the incidence increases by approximately 20 percent with every 10-year increase in age beyond the first decade of life. In addition, the incidence is slightly higher in males than in females.</p><p>There is regional variation among the variant forms of GBS with axonal forms being more common in Asia than North America or Europe, where demyelinating forms predominate. (See <a class="local">'Variant forms of Guillain-Barré syndrome'</a> below.)</p><p class="headingAnchor" id="H2"><span class="h1">CLINICAL FEATURES</span><span class="headingEndMark"> — </span>The typical clinical features of GBS include a progressive and symmetric muscle weakness and absent or depressed deep tendon reflexes. Patients may also have sensory symptoms and dysautonomia. (See <a class="local">'Examination findings'</a> below and <a class="local">'Variant forms of Guillain-Barré syndrome'</a> below.)</p><p class="headingAnchor" id="H2254080758"><span class="h2">Time course of symptoms</span><span class="headingEndMark"> — </span>Initial symptoms may become apparent and patients typically present within a few days to a week after onset of symptoms. GBS symptoms typically progress over a period of two weeks. By four weeks after onset, more than 90 percent of patients have reached the nadir of the disease [<a href="#rid99">99</a>].</p><p>Progression over four to eight weeks is sometimes called subacute inflammatory demyelinating polyradiculoneuropathy (SIDP). The management of patients with GBS symptoms within eight weeks is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5172.html" rel="external">"Guillain-Barré syndrome in adults: Treatment and prognosis", section on 'Approach to patients who relapse or worsen'</a>.)</p><p>Disease progression for more than eight weeks is consistent with the diagnosis of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). (See  <a class="medical medical_review" href="/z/d/html/5172.html" rel="external">"Guillain-Barré syndrome in adults: Treatment and prognosis", section on 'Prognosis'</a> and <a class="local">'Chronic inflammatory demyelinating polyneuropathy'</a> below.)</p><p>If the nadir is reached within 24 hours or after four weeks of symptom onset, alternative diagnoses must be considered [<a href="#rid100">100</a>]. (See <a class="local">'Differential diagnosis'</a> below.)</p><p class="headingAnchor" id="H2459374368"><span class="h2">Examination findings</span><span class="headingEndMark"> — </span>Studies of patients with GBS from the United States and Europe primarily describe patients with acute inflammatory demyelinating polyneuropathy (AIDP), the most common form of GBS [<a href="#rid88">88,99</a>]. Such symptoms may include the following.</p><p class="headingAnchor" id="H1592966291"><span class="h3">Weakness</span><span class="headingEndMark"> — </span>The weakness in GBS can vary from mild difficulty with walking to near complete paralysis of all limb, facial, respiratory, and bulbar muscles, depending on disease severity and clinical subtype.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Limb weakness</strong> – Classically, there is flaccid proximal and distal arm and leg weakness. The weakness is usually symmetric and starts in the legs, but begins in the arms or facial muscles in about 10 percent of patients. Most patients progress to weakness in both arms and legs by the nadir [<a href="#rid99">99</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cranial nerve and bulbar symptoms</strong> – Facial nerve palsies occur in more than 50 percent with AIDP, and oropharyngeal weakness eventually occurs in 50 percent [<a href="#rid99">99</a>]. Oculomotor weakness occurs in about 15 percent of patients.</p><p></p><p class="bulletIndent1">Cranial nerve symptoms including ophthalmoplegia are also diagnostic features of some variant forms of GBS. (See <a class="local">'GQ1b syndromes'</a> below.)</p><p></p><p class="bulletIndent1">Severe respiratory muscle weakness necessitating ventilatory support develops in 10 to 30 percent with GBS [<a href="#rid31">31,99,101</a>].</p><p></p><p class="headingAnchor" id="H2856297070"><span class="h3">Deep tendon reflexes</span><span class="headingEndMark"> — </span>Decreased or absent deep tendon reflexes in the arms or legs are found in approximately 90 percent of patients at presentation [<a href="#rid99">99</a>]. Most patients will develop hyporeflexia as symptoms progress to the nadir.</p><p>However, normal or even increased deep tendon reflexes may be found in some patients with GBS [<a href="#rid102">102</a>]. These include patients with the acute axonal neuropathies and Bickerstaff brainstem variant forms. Normal reflexes in GBS have also been associated with patients who report an antecedent diarrheal rather than respiratory illness [<a href="#rid102">102,103</a>]. (See <a class="local">'Variant forms of Guillain-Barré syndrome'</a> below.)</p><p>Hyperreflexia is also geographically variable, reported more frequently in cases from Japan associated with axonal forms [<a href="#rid102">102,103</a>].</p><p class="headingAnchor" id="H3751980467"><span class="h3">Other findings</span><span class="headingEndMark"> — </span>Other neurologic symptoms and autonomic dysfunction may also develop in some patients with AIDP and may be prominent features in some variant forms of GBS. (See <a class="local">'Variant forms of Guillain-Barré syndrome'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sensory involvement</strong> – Paresthesias in the hands and feet are reported by more than 80 percent of patients, but sensory abnormalities on examination are frequently mild.</p><p></p><p class="bulletIndent1">Pain due to nerve root inflammation, typically located in the back and extremities, can also be a presenting feature and is reported during the acute phase by two-thirds of patients with all forms of GBS [<a href="#rid104">104,105</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dysautonomia</strong> – The prevalence of autonomic dysfunction ranges from 38 to 70 percent of patients with GBS [<a href="#rid106">106,107</a>]. In a 2020 retrospective review of 187 GBS patients, the most frequent autonomic symptoms were [<a href="#rid107">107</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Ileus (42 percent)</p><p class="bulletIndent2"><span class="glyph">•</span>Hypertension (39 percent)</p><p class="bulletIndent2"><span class="glyph">•</span>Hypotension (37 percent)</p><p class="bulletIndent2"><span class="glyph">•</span>Fever (29 percent)</p><p class="bulletIndent2"><span class="glyph">•</span>Tachycardia or bradycardia (27 percent)</p><p class="bulletIndent2"><span class="glyph">•</span>Urinary retention (24 percent)</p><p></p><p class="bulletIndent1">Patients with dysautonomia tended to have more frequent cardiogenic complications, hyponatremia, and a higher burden of disability [<a href="#rid107">107</a>]. Mortality in patients with dysautonomia was 6 versus 0 percent in those without dysautonomia. Severe autonomic dysfunction has also been associated with sudden death [<a href="#rid108">108</a>].</p><p></p><p class="bulletIndent1">The syndrome of inappropriate antidiuretic hormone secretion (SIADH), which may be due to autonomic involvement, is an infrequent complication of GBS [<a href="#rid109">109-111</a>]. In the United States Nationwide Inpatient Sample data, SIADH was significantly more frequent in hospitalized patients with GBS compared with controls (5 versus &lt;1 percent) [<a href="#rid109">109</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Uncommon features</strong> – Unusual features of GBS include papilledema with severely elevated cerebrospinal fluid (CSF) protein, facial myokymia, hearing loss, meningeal signs, vocal cord paralysis, and mental status changes [<a href="#rid86">86</a>].</p><p></p><p class="bulletIndent1">In addition, posterior reversible encephalopathy syndrome, also known as reversible posterior leukoencephalopathy syndrome, has been associated with GBS in adults and children, likely related to acute hypertension from dysautonomia [<a href="#rid112">112-114</a>]. (See  <a class="medical medical_review" href="/z/d/html/4835.html" rel="external">"Reversible posterior leukoencephalopathy syndrome"</a>.)</p><p></p><p class="headingAnchor" id="H3472308466"><span class="h2">Variant forms of Guillain-Barré syndrome</span><span class="headingEndMark"> — </span>Historically, GBS was considered a single disorder. It now is recognized as a heterogeneous syndrome with several variant forms [<a href="#rid2">2</a>]. Variant forms of GBS may be identified by distinguishing clinical, pathophysiologic, and pathologic features. Common variant forms include:</p><p class="bulletIndent1"><span class="glyph">●</span>Acute motor axonal neuropathy (AMAN)</p><p class="bulletIndent1"><span class="glyph">●</span>Acute motor and sensory axonal neuropathy (AMSAN)</p><p class="bulletIndent1"><span class="glyph">●</span>Miller Fisher syndrome (MFS)</p><p class="bulletIndent1"><span class="glyph">●</span>Bickerstaff brainstem encephalitis (BBE)</p><p></p><p>Uncommon forms of GBS that share some features with a more common variant or have features that overlap with more than one variant form of GBS have also been described. (See <a class="local">'Rare variants'</a> below.)</p><p>The clinical forms of GBS vary according to geographic region. In an analysis of the first 1000 patients enrolled in the International Guillain-Barré Outcome Study (IGOS), the sensorimotor variant was more common among patients from North and South America than those from Bangladesh or other Asian countries (69 versus 29 versus 43 percent) [<a href="#rid31">31</a>]. By contrast, the pure motor variant was more common among those from Bangladesh than patients from other Asian countries or North and South America (69 versus 24 versus 14 percent). MFS occurred in only 1 percent of patients from Bangladesh but 11 percent of patients from North and South America and in 22 percent of patients from other countries in Asia.</p><p class="headingAnchor" id="H2295396535"><span class="h3">Acute inflammatory demyelinating polyneuropathy</span><span class="headingEndMark"> — </span>AIDP is the most common form of GBS. In the United States and Europe, AIDP represents approximately 85 to 90 percent of cases. The typical clinical features are a progressive, symmetric muscle weakness accompanied by absent or reduced deep tendon reflexes. (See <a class="local">'Clinical features'</a> above.)</p><p class="headingAnchor" id="H1231966761"><span class="h3">Acute axonal neuropathies</span><span class="headingEndMark"> — </span>AMAN and AMSAN are primary axonal forms of GBS. These forms are frequently observed in China, Japan, and Mexico, but they also comprise an estimated 5 to 10 percent of GBS cases in the United States [<a href="#rid31">31,115</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute motor axonal neuropathy</strong> – AMAN was first recognized in 1986 [<a href="#rid116">116</a>]. Most cases are preceded by <em>C. jejuni</em> infection and occur in Asia, particularly in young people [<a href="#rid21">21,31,117</a>]. AMAN is more frequent in the summer. The pathology predominantly involves axon loss.</p><p></p><p class="bulletIndent1">Deep tendon reflexes may be preserved in some patients with AMAN [<a href="#rid118">118</a>]. This form of GBS is distinguished from AIDP by its selective involvement of motor nerves. Sensory nerves are not affected. It may progress more rapidly, but the presenting clinical features of AMAN are otherwise similar to those of AIDP.</p><p></p><p class="bulletIndent1">Evidence of early axonal involvement on electrodiagnostic studies is seen as a reduction of compound muscle action potential (CMAP) amplitudes on nerve conduction studies.</p><p></p><p class="bulletIndent1">The development of AMAN has been associated with IgG antibodies to the gangliosides GM1, GD1a, GalNac-GD1a, and GD1b, which are present in peripheral nerve axons [<a href="#rid21">21</a>]. These antiganglioside antibodies can be induced by <em>C. jejuni</em> infection owing to molecular mimicry. The pathophysiology is due to antibody and complement-mediated nerve axon damage of varying severity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute motor and sensory axonal neuropathy</strong> – AMSAN is a more severe form of AMAN, in which both sensory and motor fibers are affected with marked axonal degeneration, frequently causing delayed and incomplete recovery [<a href="#rid36">36</a>]. Clinically, AMSAN resembles the AMAN variant but with additional sensory symptoms.</p><p></p><p class="bulletIndent1">Electrodiagnostic studies on patients with AMSAN show severely reduced or absent CMAP and sensory nerve action potential (SNAP) amplitudes. Axon degeneration in these patients is demonstrated by extensive active denervation needle electrode electromyography (EMG) studies.</p><p></p><p class="bulletIndent1">AMSAN is also associated with antiganglioside antibodies to GM1, GD1a, GalNac-GD1a, and GD1b [<a href="#rid119">119</a>].</p><p></p><p class="headingAnchor" id="H3028976841"><span class="h3">GQ1b syndromes</span><span class="headingEndMark"> — </span>Variant forms of GBS characterized by clinical features of impairment of eye movement (ophthalmoplegia) and ataxia rather than limb weakness are frequently associated with seropositivity to antibodies against GQ1b. The GQ1b antibody is thought to have a direct effect on the neuromuscular junctions between cranial nerves and ocular muscles [<a href="#rid120">120</a>]. The GQ1b ganglioside is a component of oculomotor nerve myelin [<a href="#rid23">23</a>]. These forms may be called anti-GQ1b syndromes and include MFS, BBE, and pharyngeal-cervical-brachial (PCB) variants [<a href="#rid121">121</a>]. The pathology appears to be chiefly due to demyelination [<a href="#rid122">122</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Miller Fisher syndrome</strong> – The clinical variant MFS, characterized by ophthalmoplegia, ataxia, and areflexia, occurs in approximately 5 to 10 percent of cases in the United States and Europe and 20 percent of cases in Asia [<a href="#rid31">31,123</a>].</p><p></p><p class="bulletIndent1">The typical presentation of MFS is that of ophthalmoplegia with ataxia and areflexia but about one-quarter of patients who present with MFS will develop some limb weakness [<a href="#rid123">123,124</a>]. Incomplete forms include acute ophthalmoplegia without ataxia and acute ataxic neuropathy without ophthalmoplegia [<a href="#rid1">1,125</a>]. Some patients with MFS develop fixed, dilated pupils [<a href="#rid126">126</a>].</p><p></p><p class="bulletIndent1">Antibodies against GQ1b (a ganglioside component of nerve) are present in 85 to 90 percent of patients with MFS [<a href="#rid127">127,128</a>].</p><p></p><p class="bulletIndent1">Electrodiagnostic studies in patients with MFS may reveal reduced or absent sensory responses without slowing of sensory conduction velocities [<a href="#rid129">129</a>]. Those with clinical weakness may show abnormalities on nerve conduction studies typical of AIDP, such as increased distal latencies or conduction block with temporal dispersion of motor responses.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bickerstaff brainstem encephalitis</strong> – BBE is a GQ1b syndrome characterized by encephalopathy with ophthalmoplegia and ataxia. In a series of 62 patients with BBE, facial weakness was present in 45 percent and bulbar symptoms including pupillary abnormalities were present in 34 percent [<a href="#rid130">130</a>]. In a review of 53 patients with BBE, approximately half were found to have mild limb weakness [<a href="#rid121">121</a>]. Reflexes were normal or brisk in 40 percent.</p><p></p><p class="bulletIndent1">BBE is not only linked to MFS by shared clinical features but is also associated with anti-GQ1b antibodies and can respond to intravenous <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> (IVIG) or plasma exchange [<a href="#rid131">131,132</a>].</p><p></p><p class="bulletIndent1">A retrospective review of the early electrophysiologic features (within 10 days) of 12 Spanish patients with BBE revealed reduced SNAP amplitudes in 5 (42 percent) patients, abnormal blink reflexes in 3 (25 percent), no signs of demyelination, and rare abnormalities in motor conductions. Interestingly, three of the patients showed normalization of SNAP amplitudes on serial neurophysiologic studies suggestive of reversible conduction failure similar to the observation in some AMAN variant cases [<a href="#rid133">133</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pharyngeal-cervical-brachial weakness </strong>– The PCB variant of GBS is characterized by acute weakness of the oropharyngeal, neck, and shoulder muscles with swallowing dysfunction [<a href="#rid134">134,135</a>]. This form may overlap with MFS or BBE [<a href="#rid134">134,136</a>].</p><p></p><p class="bulletIndent1">Patients with the PCB variant may also have facial weakness but may be distinguished from those with AIDP because leg strength and leg reflexes are usually [<a href="#rid134">134,135</a>], but not always [<a href="#rid137">137</a>], preserved.</p><p></p><p class="bulletIndent1">There are no postmortem or clinico-pathologic correlates of PCB, but detailed serial nerve conduction studies indicate a localized pattern of neuronal damage similar to AMAN [<a href="#rid1">1,134,135</a>].</p><p></p><p class="bulletIndent1">In a study of 100 PCB patients, half carried IgG anti-GT1a antibodies (associated with bulbar dysfunction), which often cross-react with GQ1b, and a quarter displayed IgG antibodies against GM1 or GD1a, which are often seen in AMAN [<a href="#rid26">26,134</a>].</p><p></p><p class="headingAnchor" id="H1368025300"><span class="h3">Rare variants</span><span class="headingEndMark"> — </span>There are a number of additional uncommon variants of GBS, including the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Paraparesis</strong> – The paraparetic variant is typically a mild type of GBS characterized by weakness and hyporeflexia limited to the lower limbs at presentation [<a href="#rid135">135,138</a>]. In a cohort of nearly 500 patients with GBS, 40 patients were characterized by a paraparetic clinical course [<a href="#rid138">138</a>]. Among these patients, intact strength in the upper extremities was found in more than 70 percent of patients, but nerve involvement in the upper extremities was frequently identified by hyporeflexia (73 percent) and abnormal nerve conductions (89 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute pandysautonomia</strong> – Patients may present with isolated acute autonomic dysfunction and hyporeflexia consistent with GBS [<a href="#rid139">139</a>]. Symptoms include diarrhea, vomiting, dizziness, abdominal pain, ileus, orthostatic hypotension, urinary retention, pupillary abnormalities, an invariant heart rate, and decreased sweating, salivation, and lacrimation. Reflexes are absent or diminished, and sensory symptoms may be present.</p><p></p><p class="bulletIndent1">Patients with pandysautonomia may respond to immunomodulatory therapies used for GBS, such as <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> [<a href="#rid139">139,140</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pure sensory GBS</strong> – GBS with isolated sensory abnormalities is a rare and heterogenous entity [<a href="#rid141">141</a>]. Reflexes are absent, and there may be minor motor involvement. An association with antibodies to GD1b has been noted [<a href="#rid142">142</a>].</p><p></p><p class="bulletIndent1">Sensory GBS may be subcategorized by nerve fiber pathology into three subtypes: acute sensory demyelinating polyneuropathy, acute sensory large-fiber axonopathy-ganglionopathy, and acute sensory small-fiber neuropathy-ganglionopathy [<a href="#rid141">141</a>].</p><p></p><p class="bulletIndent1">Patients with suspected sensory GBS should be evaluated for acute paraneoplastic sensory neuronopathy, which is likelier to present with asymmetric sensory loss and severe ataxia. (See  <a class="medical medical_review" href="/z/d/html/5096.html" rel="external">"Approach to the patient with sensory loss", section on 'Sensory neuronopathies'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Facial diplegia and distal limb paresthesia</strong> – Case series have described patients with acute-onset bilateral facial weakness with paresthesias of the limbs [<a href="#rid136">136,143,144</a>]. Other bulbar symptoms are typically absent and electrodiagnostic studies show abnormalities suggestive of demyelinating pathology consistent with GBS.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute bulbar palsy</strong> – Patients may also present with areflexia, ophthalmoplegia, ataxia, and facial palsy; neck and limb weakness are absent [<a href="#rid145">145</a>]. This rare form overlaps with both MFS and PCB variants of GBS.</p><p></p><p class="headingAnchor" id="H10"><span class="h1">DIAGNOSTIC EVALUATION</span><span class="headingEndMark"> — </span>The initial diagnosis of GBS is based on the clinical features consistent with the syndrome: acute onset of progressive, mostly symmetric muscle weakness and reduced or absent deep tendon reflexes. The weakness can vary from mild difficulty with walking to nearly complete paralysis of all extremity, facial, respiratory, and bulbar muscles. Symptoms typically progress over days to four weeks. (See <a class="local">'Clinical features'</a> above.)</p><p>The clinical diagnosis of GBS is supported by results of diagnostic testing such as cerebrospinal fluid (CSF) and electrodiagnostic studies [<a href="#rid75">75</a>]. Lumbar puncture for CSF evaluation is performed in all patients. Electrodiagnostic studies and imaging are performed in patients with atypical symptoms and whenever the initial CSF evaluation is nondiagnostic  (<a class="graphic graphic_algorithm graphicRef134174" href="/z/d/graphic/134174.html" rel="external">algorithm 1</a>). These diagnostic tests may also help to exclude alternative diagnoses [<a href="#rid146">146</a>]. (See <a class="local">'Cerebrospinal fluid analysis'</a> below and <a class="local">'Electrodiagnostic studies'</a> below.)</p><p class="headingAnchor" id="H374051631"><span class="h2">Diagnostic criteria</span><span class="headingEndMark"> — </span>Diagnostic criteria for GBS, originally proposed for research in 1978 by the National Institute of Neurological Disorders and Stroke (NINDS) [<a href="#rid147">147</a>], are widely used in clinical practice. These criteria are based on expert consensus and have been modified over time to reflect advances in the understanding of GBS [<a href="#rid75">75,148</a>].</p><p>Required features include:</p><p class="bulletIndent1"><span class="glyph">●</span>Progressive weakness of the arms and/or legs, ranging from minimal weakness of the legs to total paralysis of all four limbs, and including the trunk, bulbar and facial muscles, and external ophthalmoplegia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Areflexia or decreased deep tendon reflexes in weak limbs.</p><p></p><p>Supportive features include:</p><p class="bulletIndent1"><span class="glyph">●</span>Symptom progression over days to four weeks</p><p class="bulletIndent1"><span class="glyph">●</span>Relatively symmetric, bilateral symptoms</p><p class="bulletIndent1"><span class="glyph">●</span>Pain in the trunk or limbs</p><p class="bulletIndent1"><span class="glyph">●</span>Cranial nerve symptoms or signs</p><p class="bulletIndent1"><span class="glyph">●</span>Autonomic dysfunction</p><p class="bulletIndent1"><span class="glyph">●</span>Sensory dysfunction that is mild</p><p class="bulletIndent1"><span class="glyph">●</span>No fever at symptom onset</p><p class="bulletIndent1"><span class="glyph">●</span>CSF with elevated protein and normal to mildly elevated leukocyte count (usually &lt;5 cells/mm<sup>3</sup>)</p><p class="bulletIndent1"><span class="glyph">●</span>Electrodiagnostic abnormalities consistent with GBS</p><p class="bulletIndent1"><span class="glyph">●</span>Recovery starting two to four weeks after progression halts</p><p></p><p>An epidemiologic study in Italy found that 84 percent of patients with GBS fulfilled the NINDS criteria and 16 percent had a variant syndrome [<a href="#rid149">149</a>]. Patients with GBS who do not meet the required criteria will typically have symptoms consistent with one of the other variant forms of GBS variants. As examples, patients with acute motor axonal neuropathy (AMAN) may have acute and progressive symmetric limb weakness but reflexes may be retained; those with Miller Fisher syndrome (MFS) may have acute and progressive ophthalmoplegia with reduced reflexes but no limb weakness. (See <a class="local">'Examination findings'</a> above and <a class="local">'Variant forms of Guillain-Barré syndrome'</a> above.)</p><p>Patients with symptoms that do not meet diagnostic criteria for GBS or a variant form should be evaluated for alternative causes. (See <a class="local">'Additional diagnostic tests for some patients'</a> below and <a class="local">'Differential diagnosis'</a> below.)</p><p>The World Health Organization recommends use of the Brighton criteria  (<a class="graphic graphic_table graphicRef107091" href="/z/d/graphic/107091.html" rel="external">table 1</a>) for the case definition of GBS in regions affected by Zika virus transmission [<a href="#rid150">150</a>]. The Brighton criteria are developed for research studies and exclude most clinical variants of GBS. (See  <a class="medical medical_review" href="/z/d/html/106169.html" rel="external">"Zika virus infection: An overview"</a>.)</p><p class="headingAnchor" id="H11"><span class="h2">Cerebrospinal fluid analysis</span><span class="headingEndMark"> — </span>Lumbar puncture for CSF analysis should be performed in all patients to confirm the GBS diagnosis and exclude other sources to the symptoms. The typical finding with lumbar puncture in patients with GBS is an elevated CSF protein with a normal white blood cell count. This finding is called an albuminocytologic dissociation. The elevated protein may be due to increased permeability of the blood-nerve barrier at the level of the proximal nerve roots.</p><p class="bulletIndent1"><span class="glyph">●</span>CSF protein elevations varied in one study from 45 to 200 mg/dL (0.45 to 2.0 g/L) for most patients, but protein elevations as high as 1000 mg/dL (10 g/L) have also been described [<a href="#rid86">86</a>].</p><p></p><p class="bulletIndent1">The albuminocytologic dissociation varies by time since symptom onset. It may be present in 50 to 66 percent of patients in the first week after the onset of symptoms and ≥75 percent of patients in the third week [<a href="#rid1">1,86,151,152</a>]. In an analysis of 1231 patients from the International Guillain-Barré Outcome Study (IGOS), an albuminocytologic dissociation increased from 57 percent among patients ≤4 days from onset of weakness to 84 percent for those &gt;4 days from onset of weakness [<a href="#rid153">153</a>]. GBS features associated with albuminocytologic dissociation included proximal or diffuse weakness and demyelinating subtype. In some series, a normal CSF protein is found in one-third to one-half of patients when tested earlier than one week from symptom onset and therefore does not exclude the diagnosis of GBS [<a href="#rid99">99</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The CSF cell count is typically normal (ie, &lt;5 cells/mm<sup>3</sup>) but may be elevated up to 50 cells/mm<sup>3</sup>. However, a minority of patients with GBS have mildly elevated CSF cell counts [<a href="#rid153">153</a>]. In one study, the cell count was &lt;5 cells/mm<sup>3</sup> in 87 percent of patients, 5 to 10 cells/mm<sup>3</sup> in 9 percent, and 11 to 30 cells/mm<sup>3</sup> and &gt;30 cells/mm<sup>3</sup> in 2 and 2 percent of patients, respectively [<a href="#rid86">86</a>]. A review of 494 adult patients with GBS similarly found a mild CSF pleocytosis of 5 to 50 cells/mm<sup>3 </sup>present in 15 percent, and none had a pleocytosis &gt;50 cells/mm<sup>3</sup> [<a href="#rid99">99</a>].</p><p></p><p class="bulletIndent1">A CSF pleocytosis is common in patients who have GBS and concurrent HIV infection [<a href="#rid47">47</a>].</p><p></p><p class="bulletIndent1">The routine analysis of CSF for GBS includes cell count and differential, protein, glucose, Gram stain, and culture. Any remaining CSF should be retained for possible further analysis if the results of the initial routine analysis show a significant pleocytosis or other finding suggestive of an alternative diagnosis. (See <a class="local">'Differential diagnosis'</a> below.)</p><p></p><p class="headingAnchor" id="H829093397"><span class="h2">Electrodiagnostic studies</span><span class="headingEndMark"> — </span>Electrodiagnostic studies consist of nerve conduction studies (NCS) and electromyography (EMG) and are performed in most patients to support the diagnosis of GBS as well as to provide prognostic information regarding the nature and severity of nerve dysfunction. They may be performed serially, at presentation and again several weeks later, to monitor recovery. However, electrodiagnostic testing may not be needed for the diagnosis of GBS in patients with typical symptoms who are found to have an albuminocytologic dissociation on CSF analysis. In addition, testing may be unavailable in some settings, and findings may be normal early in the disease course. Electrodiagnostic results may be limited in the intensive care or other inpatient settings due to technical and electrical artifacts or when patients are sedated and unable to participate in the assessment of volitional motor activity.</p><p>If electrodiagnostic testing performed at initial presentation is nondiagnostic, repeat testing may be performed one to two weeks after the first study. Abnormal findings are typically most pronounced approximately three to four weeks after the onset of weakness [<a href="#rid154">154</a>].</p><p>Progression of abnormal findings that support the diagnosis of the common demyelinating forms of GBS include [<a href="#rid155">155-158</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Prolonged or absent F waves and absent H reflexes as the earliest findings</p><p class="bulletIndent1"><span class="glyph">●</span>Increased distal latencies and conduction blocks with temporal dispersion of motor responses</p><p class="bulletIndent1"><span class="glyph">●</span>Significant slowing or absent response on nerve conduction velocities not seen until the third or fourth week</p><p class="bulletIndent1"><span class="glyph">●</span>Needle EMG of weak muscles showing reduced recruitment or denervation</p><p></p><p>Sural sparing, when noted, also reinforces the suspicion for GBS since this finding is usually not observed in length dependent neuropathies [<a href="#rid159">159</a>]. Ancillary studies, such as facial NCS and blink reflex testing, may be used to show abnormal conduction in patients with GBS and bulbar symptoms.</p><p>Electrodiagnostic studies may also be useful to identify the main variants of GBS by identifying demyelinating (eg, acute inflammatory demyelinating polyneuropathy) or axonal (eg, AMAN) pathophysiology [<a href="#rid75">75</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Demyelinating forms of GBS are supported by features of demyelination, including increased F wave latency, prolonged distal motor latency, conduction blocks, temporal dispersion, and decreased motor nerve conduction velocity [<a href="#rid154">154</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Axonal forms of GBS are supported by decreased distal motor and/or sensory amplitudes [<a href="#rid154">154</a>]. In contrast with demyelinating forms, there is typically no sensory nerve involvement and F waves may be absent but are not significantly prolonged. In addition, there is no significant slowing of conduction velocities, increase in distal latencies, or temporal dispersion.</p><p></p><p>However, the low distal CMAP amplitudes in axonal forms may be associated with conduction block, a feature more typical of demyelinating forms of GBS [<a href="#rid160">160</a>]. Conduction block in axonal form is typically reversible, and the CMAP amplitudes rapidly improve with early recovery of function [<a href="#rid160">160-162</a>]. Electrophysiologic diagnosis to distinguish AMAN associated with reversible conduction block cases is more reliable when performed at three to six weeks after GBS onset rather than the first two weeks [<a href="#rid163">163-165</a>].</p><p>In 745 participants in the International Guillain-Barré Outcome Study classified by electrodiagnostic studies, 52 percent had a demyelinating pathophysiology, 10 percent axonal, 3 percent inexcitable nerves, while 29 percent were notably equivocal, and 7 percent had normal electrodiagnostic testing. Overall, patients with the axonal variants of GBS were younger than patients with demyelination [<a href="#rid31">31</a>].</p><p>Electrodiagnostic findings in patients with specific GBS variants are also discussed above. (See <a class="local">'Variant forms of Guillain-Barré syndrome'</a> above.)</p><p class="headingAnchor" id="H3060574674"><span class="h2">Laboratory testing</span><span class="headingEndMark"> — </span>We perform initial screening laboratory testing in all patients to screen other causes of acute weakness. This includes:</p><p class="bulletIndent1"><span class="glyph">●</span>Complete blood count and differential</p><p class="bulletIndent1"><span class="glyph">●</span>Comprehensive metabolic profile</p><p class="bulletIndent1"><span class="glyph">●</span>Erythrocyte sedimentation rate (ESR)</p><p class="bulletIndent1"><span class="glyph">●</span>Serum glucose and glycosylated hemoglobin</p><p></p><p>Additional testing to evaluate for other causes of acute weakness may be indicated by specific symptoms, risk factors, and clinical settings  (<a class="graphic graphic_table graphicRef64055" href="/z/d/graphic/64055.html" rel="external">table 2</a>). (See <a class="local">'Differential diagnosis'</a> below and  <a class="medical medical_review" href="/z/d/html/5284.html" rel="external">"Overview of polyneuropathy"</a>.)</p><p class="headingAnchor" id="H1516507001"><span class="h2">Additional diagnostic tests for some patients</span><span class="headingEndMark"> — </span>For patients with atypical clinical features or those with equivocal results on CSF analysis and electrodiagnostic studies, antibody testing and neuroimaging are obtained to support the diagnosis of GBS and to exclude alternative possibilities.</p><p class="headingAnchor" id="H13"><span class="h3">Autoantibody testing</span><span class="headingEndMark"> — </span>Antiganglioside antibody testing may be useful in clinical practice to help identify patients with atypical symptoms that may be suggestive of a variant form of GBS. (See <a class="local">'Variant forms of Guillain-Barré syndrome'</a> above.)</p><p>The serum of patients with acute axonal neuropathies such as AMAN and acute motor and sensory axonal neuropathy (AMSAN) have frequently been found to have anti-GM1 IgG and anti-GD1a antibodies [<a href="#rid21">21,166</a>]. Anti-GalNac-GD1a and anti-GD1b have also been associated with axonal forms of GBS [<a href="#rid167">167,168</a>]. Anti-GM2 IgM antibodies have been noted in 30 to 50 percent of patients with cytomegalovirus (CMV)-associated GBS, but anti-GM2 antibodies also occur in patients with CMV who do not have GBS [<a href="#rid169">169,170</a>]. (See <a class="local">'Acute axonal neuropathies'</a> above.)</p><p>Serum IgG antibodies to GQ1b are useful for the diagnosis of MFS, having a sensitivity of 85 to 90 percent. GQ1b is a component of oculomotor nerve myelin and may also be present in patients with Bickerstaff brainstem encephalitis, the pharyngeal-cervical brachial (PCB) variant, and other patients with GBS with ophthalmoplegia [<a href="#rid127">127,128</a>]. Anti-GT1a antibodies that cross-react with GQ1b have been reported in patients with the PCB variant [<a href="#rid26">26</a>]. (See <a class="local">'GQ1b syndromes'</a> above.)</p><p>Some patients with PCB form of GBS may have antibodies against GM1 or GD1a, which are more frequently seen in patients with AMAN who also present with prominent motor weakness [<a href="#rid26">26,134</a>].</p><p class="headingAnchor" id="H3777576043"><span class="h3">Diagnostic imaging</span><span class="headingEndMark"> — </span>Diagnostic imaging is typically reserved for patients with atypical symptoms to exclude alternative causes. This includes patients with prominent early bowel or bladder dysfunction, those who present with a sensory level, and those who reach a clinical nadir within 24 hours of symptom onset. Imaging is also warranted for patients with clinical symptoms of GBS when CSF and electrodiagnostic studies are not confirmatory. (See <a class="local">'Differential diagnosis'</a> below.)</p><p>For most patients with symptoms of GBS who are evaluated with diagnostic imaging, we obtain magnetic resonance imaging (MRI) of the brain and spine with contrast. MRI of the brain and cervical spine imaging is typically performed for patients with bulbar weakness and/or quadriparesis, while MRI of the thoracic and lumbar spine imaging is performed for those with lower extremity weakness to evaluate for transverse myelitis or another cause for myelopathy.</p><p>In addition, features consistent with GBS may be identified on imaging of the spine or nerves:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>MRI</strong> – Spinal MRI  (<a class="graphic graphic_diagnosticimage graphicRef114440" href="/z/d/graphic/114440.html" rel="external">image 1</a>) may reveal thickening and enhancement of the intrathecal spinal nerve roots and cauda equina [<a href="#rid171">171-174</a>]. The anterior spinal nerve roots may be selectively involved, but, in other cases, both the anterior and posterior spinal nerve roots are involved.</p><p></p><p class="bulletIndent1">In exceptional cases of MFS, abnormalities of the spinal cord posterior columns have been described [<a href="#rid174">174</a>]. On brain MRI, enhancement of the oculomotor, abducens, and facial nerves may be seen  (<a class="graphic graphic_diagnosticimage graphicRef114440" href="/z/d/graphic/114440.html" rel="external">image 1</a>) [<a href="#rid172">172,173,175</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ultrasound</strong> – Peripheral nerve ultrasound may identify structural changes associated with GBS. Patients with GBS may have enlarged cervical nerve roots acutely and show progressive improvement of cross-sectional area of peripheral nerves on serial ultrasound studies during recovery [<a href="#rid176">176-178</a>]. Sparing of sensory nerves on ultrasound and transient enlargement of nerve roots and the vagus nerve may help differentiate GBS from chronic inflammatory demyelinating polyradiculoneuropathy, and ultrasonographic normalization of nerves evaluated at six months lends further confirmation of the diagnosis of GBS [<a href="#rid179">179</a>].</p><p></p><p class="headingAnchor" id="H15"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of GBS includes chronic inflammatory demyelinating polyneuropathy (CIDP) and other acute polyneuropathies as well as diseases of the spinal cord, neuromuscular junction, and muscle  (<a class="graphic graphic_table graphicRef80040" href="/z/d/graphic/80040.html" rel="external">table 3</a>).</p><p>The differential diagnosis of variant forms of GBS characterized by prominent ophthalmoplegia and ataxia additionally includes cerebral and brainstem pathologies. (See <a class="local">'Differential diagnosis of Miller Fisher syndrome'</a> below.)</p><p>The following features make the diagnosis of GBS doubtful:</p><p class="bulletIndent1"><span class="glyph">●</span>Weakness progresses to nadir &lt;24 hours or &gt;4 weeks from symptom onset</p><p class="bulletIndent1"><span class="glyph">●</span>Sensory level (decrement or loss of sensation below a spinal cord root level)</p><p class="bulletIndent1"><span class="glyph">●</span>Asymmetric weakness</p><p class="bulletIndent1"><span class="glyph">●</span>Bowel and bladder dysfunction at onset or that becomes severe and persistent</p><p class="bulletIndent1"><span class="glyph">●</span>Pulmonary dysfunction with little or no limb weakness at onset</p><p class="bulletIndent1"><span class="glyph">●</span>Sensory signs that are isolated or with no weakness at onset</p><p class="bulletIndent1"><span class="glyph">●</span>Fever at onset</p><p class="bulletIndent1"><span class="glyph">●</span>Cerebrospinal fluid (CSF) leukocyte count &gt;50/mm<sup>3</sup></p><p></p><p>Patients with any of these features should be evaluated for alternative sources to symptoms. As examples, brain and/or spine magnetic resonance imaging (MRI) may be warranted when central etiologies are suspected by the presence of a sensory level, prominent bowel/bladder dysfunction, or weakness progressing to nadir &lt;24 hours from symptom onset. By contrast, additional laboratory testing may be indicated for patients with prominent sensory signs and those with fever at onset  (<a class="graphic graphic_table graphicRef64055" href="/z/d/graphic/64055.html" rel="external">table 2</a>). Evaluation for inflammatory conditions such as transverse myelitis are warranted for patients with a CSF leukocyte count &gt;50 mm<sup>3</sup>  (<a class="graphic graphic_table graphicRef88912" href="/z/d/graphic/88912.html" rel="external">table 4</a>). (See <a class="local">'Additional diagnostic tests for some patients'</a> above.)</p><p class="headingAnchor" id="H16"><span class="h2">Chronic inflammatory demyelinating polyneuropathy</span><span class="headingEndMark"> — </span>There is a temporal continuum between acute inflammatory demyelinating polyneuropathy (AIDP), the demyelinating form of GBS, and CIDP.</p><p class="bulletIndent1"><span class="glyph">●</span>AIDP is a monophasic subacute illness that typically reaches its nadir within two to four weeks. (See <a class="local">'Time course of symptoms'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Subacute inflammatory demyelinating polyneuropathy (SIDP) is the term used by some authors for symptoms that reach a nadir between four and eight weeks.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CIDP continues to progress or has relapses for greater than eight weeks. (See  <a class="medical medical_review" href="/z/d/html/5264.html" rel="external">"Chronic inflammatory demyelinating polyneuropathy: Etiology, clinical features, and diagnosis"</a>.)</p><p></p><p>This arbitrary temporal delineation between GBS and CIDP can occasionally be difficult to ascertain in practice. Examination of the patient over time and serial electrodiagnostic studies or peripheral nerve ultrasound can help clarify whether the clinical course is that of AIDP or CIDP [<a href="#rid179">179</a>]. (See <a class="local">'Electrodiagnostic studies'</a> above and <a class="local">'Diagnostic imaging'</a> above.)</p><p>Features may be useful to distinguish GBS from CIDP:</p><p class="bulletIndent1"><span class="glyph">●</span>The onset of GBS is usually easily identified, while the precise onset of CIDP is typically less clear.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antecedent events are identified more frequently with GBS than CIDP (approximately 70 percent of GBS cases versus &lt;30 percent of CIDP cases).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Clinical features in the first few weeks after onset of symptoms suggestive of CIDP over GBS include [<a href="#rid180">180</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Acute relapse or deterioration occurs ≥3 times</p><p class="bulletIndent2"><span class="glyph">•</span>Deterioration occurs ≥8 weeks after symptom onset</p><p class="bulletIndent2"><span class="glyph">•</span>Mild symptoms with retained ability to walk independently throughout course</p><p class="bulletIndent2"><span class="glyph">•</span>Lack of either cranial neuropathies or frequent respiratory involvement</p><p></p><p>About 2 to 5 percent of patients initially diagnosed with AIDP will develop the chronic relapsing weakness of CIDP. (See  <a class="medical medical_review" href="/z/d/html/5172.html" rel="external">"Guillain-Barré syndrome in adults: Treatment and prognosis", section on 'Approach to patients who relapse or worsen'</a>.)</p><p class="headingAnchor" id="H17"><span class="h2">Other polyneuropathies</span><span class="headingEndMark"> — </span>Several polyneuropathies may mimic GBS by presenting with an abrupt symptom onset. The combination of data from the clinical setting, screening laboratory tests indicated by presentation and risk factors, and cerebrospinal fluid analysis and nerve conduction studies, are usually sufficient to identify or rule out these other causes of polyneuropathy.</p><p>Specific etiologies include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thiamine (vitamin B1) deficiency</strong> – Adults with thiamine deficiency from nutritional deficiencies or chronic alcohol use typically present with a symmetric, distal motor and sensory polyneuropathy. (See  <a class="medical medical_review" href="/z/d/html/5367.html" rel="external">"Overview of water-soluble vitamins", section on 'Deficiency'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute arsenic poisoning</strong> – Patients with arsenic poisoning may present with distal, sensory-predominating neurologic symptoms. A history of environmental exposure and associated skin or nail changes may be seen. Urine testing is useful to identify arsenic toxicity. (See  <a class="medical medical_review" href="/z/d/html/2778.html" rel="external">"Arsenic exposure and chronic poisoning", section on 'Neurologic'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Toxic neuropathies</strong> – Exposure to toxic substances such as n-hexane exposure (in "glue sniffing neuropathy") may lead to an acute polyneuropathy. (See  <a class="medical medical_review" href="/z/d/html/5284.html" rel="external">"Overview of polyneuropathy", section on 'Toxic'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lyme disease</strong> – Neurologic manifestations of borreliosis are varied and include peripheral polyneuropathy, cranial nerve palsies (eg, facial nerve palsy), and ataxia. Laboratory and CSF testing identifies Lyme disease. (See  <a class="medical medical_review" href="/z/d/html/7913.html" rel="external">"Clinical manifestations of Lyme disease in adults", section on 'Neurologic manifestations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tick paralysis</strong> – Patients with tick paralysis may present with bulbar or limb weakness. Symptoms may be asymmetric. Laboratory and CSF testing is typically normal. Symptoms typically improve promptly following removal of the embedded tick. (See  <a class="medical medical_review" href="/z/d/html/7900.html" rel="external">"Tick paralysis", section on 'Clinical manifestations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Systemic vasculitis</strong> – Peripheral nerve vasculitis may present with mononeuritis multiplex of sensory and motor fibers in the distribution of individual peripheral nerves. Although the pathology of the disease is asymmetric, the clinical picture can mimic GBS with symmetric ascending weakness when the vasculitis is rapidly progressive with confluent nerve involvement. Patients may also have severe limb pain and systemic symptoms such as fever, weight loss, and other organ involvement. Serological testing, electrophysiologic testing, and biopsy of nerve and muscle lead to the diagnosis. (See  <a class="medical medical_review" href="/z/d/html/8236.html" rel="external">"Clinical manifestations and diagnosis of vasculitic neuropathies"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>HIV/AIDS</strong> – Patients with HIV and severe immunosuppression or AIDS may develop acute and progressive lumbosacral polyradiculopathy. This may be due to opportunistic infections such as cytomegalovirus. Weakness may be asymmetric and patients may develop bowel and/or bladder dysfunction. CSF typically shows a lymphocytic pleocytosis. (See  <a class="medical medical_review" href="/z/d/html/14149.html" rel="external">"Polyradiculopathy: Spinal stenosis, infectious, carcinomatous, and inflammatory nerve root syndromes", section on 'Polyradiculopathy in HIV and AIDS'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sarcoidosis</strong> – Patients with sarcoidosis may present with peripheral polyneuropathy and/or cranial neuropathies, sometimes in the absence of other systemic symptoms. An elevated angiotensin converting enzyme level in the blood or CSF and meningeal enhancement on brain or spine imaging supports the diagnosis. (See  <a class="medical medical_review" href="/z/d/html/4834.html" rel="external">"Neurologic sarcoidosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Porphyria</strong> – Acute intermittent porphyria may present with a progressive sensory and motor neuropathy. Symptoms may begin in the upper limbs and can be associated with autonomic dysfunction as well as abdominal pain. A spot urine test for porphobilinogen in a sample obtained at the time of symptoms will identify most patients with acute porphyria. (See  <a class="medical medical_review" href="/z/d/html/7096.html" rel="external">"Acute intermittent porphyria: Pathogenesis, clinical features, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Leptomeningeal lymphoma</strong> – Malignant involvement of the meninges may present with a peripheral neuropathy but may have other neurologic symptoms such as headache, encephalopathy, or cranial nerve palsies. (See  <a class="medical medical_review" href="/z/d/html/4720.html" rel="external">"Secondary central nervous system lymphoma: Clinical features and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Paraneoplastic syndromes</strong> – Peripheral motor or sensorimotor neuropathies can occur in patients with systemic cancer. The diagnosis may be suspected in patients with known systemic cancer and patients with other neurologic manifestations such as encephalopathy. Diagnostic evaluation may include imaging for malignancy, CSF analysis, and specific antibody testing. (See  <a class="medical medical_review" href="/z/d/html/5188.html" rel="external">"Overview of paraneoplastic syndromes of the nervous system"</a>.)</p><p></p><p class="headingAnchor" id="H18"><span class="h2">Spinal cord disorders</span><span class="headingEndMark"> — </span>Acute myelopathies can be confused with GBS since reflexes can be depressed in the acute stage of spinal cord disease. Examples include:</p><p class="bulletIndent1"><span class="glyph">●</span>Acute transverse myelitis (see  <a class="medical medical_review" href="/z/d/html/14088.html" rel="external">"Transverse myelitis: Etiology, clinical features, and diagnosis"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Spinal cord compression from fracture or epidural abscess (see  <a class="medical medical_review" href="/z/d/html/1292.html" rel="external">"Spinal epidural abscess"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Spinal cord infarction (see  <a class="medical medical_review" href="/z/d/html/1117.html" rel="external">"Spinal cord infarction: Clinical presentation and diagnosis"</a>)</p><p></p><p>Distinguishing features favoring a spinal cord disorder include early bowel and bladder dysfunction, a sensory level on examination, and/or an elevated CSF leukocyte count  (<a class="graphic graphic_table graphicRef88912" href="/z/d/graphic/88912.html" rel="external">table 4</a>). Spine MRI is usually helpful in identifying a focal spinal cord lesion consistent with acute myelopathy. (See  <a class="medical medical_review" href="/z/d/html/5093.html" rel="external">"Disorders affecting the spinal cord"</a>.)</p><p>Motor neuron disorders such as amyotrophic lateral sclerosis, progressive spinal muscular atrophy, and poliomyelitis may also mimic GBS. These are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5136.html" rel="external">"Clinical features of amyotrophic lateral sclerosis and other forms of motor neuron disease"</a> and  <a class="medical medical_review" href="/z/d/html/5138.html" rel="external">"Diagnosis of amyotrophic lateral sclerosis and other forms of motor neuron disease"</a> and  <a class="medical medical_review" href="/z/d/html/6146.html" rel="external">"Spinal muscular atrophy"</a> and  <a class="medical medical_review" href="/z/d/html/5143.html" rel="external">"Poliomyelitis and post-polio syndrome", section on 'Poliomyelitis'</a>.)</p><p class="headingAnchor" id="H19"><span class="h2">Neuromuscular junction disorders</span><span class="headingEndMark"> — </span>Diseases of the neuromuscular junction including botulism, myasthenia gravis, and Lambert-Eaton myasthenic syndrome can all present with acute weakness, but sensory signs or symptoms are lacking. Botulism is associated with large, unreactive pupils and constipation, though similar pupillary abnormalities may occur in a subset of patients with GQ1b syndromes. Electromyography with repetitive nerve stimulation and appropriate laboratory tests help clarify the diagnosis. (See  <a class="medical medical_review" href="/z/d/html/5130.html" rel="external">"Diagnosis of myasthenia gravis"</a> and  <a class="medical medical_review" href="/z/d/html/5174.html" rel="external">"Lambert-Eaton myasthenic syndrome: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/5509.html" rel="external">"Botulism"</a> and <a class="local">'GQ1b syndromes'</a> above.)</p><p class="headingAnchor" id="H20"><span class="h2">Muscle disorders</span><span class="headingEndMark"> — </span>Acute polymyositis, dermatomyositis, necrotizing myopathy, and critical illness myopathy can present with acute and symmetric weakness similar to GBS. Patients with myopathies may report muscle or joint pain and characteristic skin findings. A myopathic cause to weakness is supported by laboratory and electrodiagnostic testing and by muscle biopsy. The myopathy of critical illness (often combined with neuropathy) presents as an acute paralysis, typically in patients receiving intensive care. (See  <a class="medical medical_review" href="/z/d/html/5159.html" rel="external">"Clinical manifestations of dermatomyositis and polymyositis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/127066.html" rel="external">"Overview of and approach to the idiopathic inflammatory myopathies"</a> and  <a class="medical medical_review" href="/z/d/html/5144.html" rel="external">"Neuromuscular weakness related to critical illness"</a>.)</p><p class="headingAnchor" id="H21"><span class="h2">Differential diagnosis of Miller Fisher syndrome</span><span class="headingEndMark"> — </span>The Miller Fisher syndrome (MFS) may be mistaken for a brainstem stroke due to prominent ophthalmoplegia with ataxia often without associated limb weakness found in other forms of GBS. The gradual onset and progressive nature of MFS symptoms may help to distinguish from an acute stroke. (See <a class="local">'GQ1b syndromes'</a> above.)</p><p>The differential diagnosis of MFS also includes other cerebral disorders. These include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Wernicke encephalopathy</strong> – Patients with Wernicke encephalopathy usually have encephalopathy and nystagmus, features not usually associated with MFS. Of note, nystagmus has been reported in an acute vestibular syndrome associated with anti-GQ1b antibodies [<a href="#rid181">181</a>]. Neuroimaging studies can be helpful to exclude stroke and to demonstrate the acute lesions of the diencephalon, midbrain, and periventricular regions that are sometimes found in patients with Wernicke encephalopathy. (See  <a class="medical medical_review" href="/z/d/html/4818.html" rel="external">"Wernicke encephalopathy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Myasthenia gravis</strong> – Myasthenia gravis and other neuromuscular junction disorders that may present with cranial nerve abnormalities may be mistaken for MFS. Appropriate laboratory and electrodiagnostic testing with repetitive nerve stimulation help differentiate MFS from neuromuscular junction disorders. (See  <a class="medical medical_review" href="/z/d/html/5170.html" rel="external">"Clinical manifestations of myasthenia gravis"</a> and  <a class="medical medical_review" href="/z/d/html/5130.html" rel="external">"Diagnosis of myasthenia gravis"</a> and  <a class="medical medical_review" href="/z/d/html/14147.html" rel="external">"Electrodiagnostic evaluation of the neuromuscular junction"</a>.)</p><p></p><p class="headingAnchor" id="H1626266045"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/114912.html" rel="external">"Society guideline links: Guillain-Barré syndrome"</a>.)</p><p class="headingAnchor" id="H3077628"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/82816.html" rel="external">"Patient education: Guillain-Barré syndrome (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H22"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition and pathogenesis</strong> – The acute immune-mediated polyneuropathies are classified under the eponym Guillain-Barré syndrome (GBS). The acute polyneuropathy of GBS is triggered when an immune response to an antecedent event cross-reacts with shared epitopes on peripheral nerve (molecular mimicry). (See <a class="local">'Introduction'</a> above and <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antecedent triggers</strong> – Most patients report an antecedent infection or other event in the four weeks prior to GBS. Upper respiratory tract infection and gastroenteritis are the most common infections, and <em>Campylobacter jejuni</em> gastroenteritis is the most commonly identified precipitant of GBS. (See <a class="local">'Antecedent events'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – GBS occurs worldwide with an overall incidence of 1 to 2 cases per 100,000 per year. The incidence increases by approximately 20 percent with every 10-year increase in age. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – The typical clinical features of GBS include progressive and symmetric muscle weakness with absent or depressed deep tendon reflexes. Patients may also have sensory symptoms and dysautonomia. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>GBS symptoms typically progress over a period of two weeks. If the nadir is reached within 24 hours or after 4 weeks of symptom onset, alternative diagnoses must be considered. (See <a class="local">'Time course of symptoms'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>GBS is a heterogeneous syndrome with variant forms that may be identified by distinguishing clinical and pathologic features. Acute inflammatory demyelinating polyneuropathy is the most common form of GBS. Common variant forms include acute motor axonal neuropathy, acute motor and sensory axonal neuropathy, Miller Fisher syndrome, and Bickerstaff brainstem encephalitis. (See <a class="local">'Examination findings'</a> above and <a class="local">'Variant forms of Guillain-Barré syndrome'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnostic evaluation</strong> – The initial diagnosis of GBS is based on the clinical features consistent with the syndrome: acute onset of progressive, mostly symmetric muscle weakness, and reduced or absent deep tendon reflexes. The clinical diagnosis of GBS is confirmed if cerebrospinal fluid (CSF) and electrodiagnostic studies show typical abnormalities  (<a class="graphic graphic_algorithm graphicRef134174" href="/z/d/graphic/134174.html" rel="external">algorithm 1</a>). (See <a class="local">'Diagnostic evaluation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>CSF findings in patients with GBS is an albuminocytologic dissociation consisting of an elevated CSF protein (typically 45 to 200 mg/dL [0.45 to 2.0 g/L]) with a normal white blood cell count (typically &lt;5 cells/mm<sup>3</sup> but may be elevated up to 50 cells/mm<sup>3</sup>). (See <a class="local">'Cerebrospinal fluid analysis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Electrodiagnostic studies may show prolonged or absent F waves and absent H reflexes, increased distal latencies and conduction blocks with temporal dispersion, significant slowing or absent response on nerve conduction velocities, and reduced recruitment or denervation on needle electromyography of weak muscles. (See <a class="local">'Electrodiagnostic studies'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Laboratory testing is performed for all patients to screen other common causes of acute weakness. We reserve ganglioside autoantibody testing for patients with symptoms suggestive of a variant form of GBS. Neuroimaging is typically used for patients with atypical symptoms to exclude alternative etiologies. (See <a class="local">'Additional diagnostic tests for some patients'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – The differential diagnosis of GBS includes chronic inflammatory demyelinating polyneuropathy, other acute polyneuropathies, and diseases of the spinal cord, neuromuscular junction, and muscle  (<a class="graphic graphic_table graphicRef80040" href="/z/d/graphic/80040.html" rel="external">table 3</a>). Patients with features atypical for GBS should be evaluated for alternative sources to symptoms  (<a class="graphic graphic_algorithm graphicRef134174" href="/z/d/graphic/134174.html" rel="external">algorithm 1</a>). (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="headingAnchor" id="H1861162176"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Francine J Vriesendorp, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Yuki N, Hartung HP. Guillain-Barré syndrome. N Engl J Med 2012; 366:2294.</a></li><li><a class="nounderline abstract_t">Shahrizaila N, Lehmann HC, Kuwabara S. Guillain-Barré syndrome. Lancet 2021; 397:1214.</a></li><li><a class="nounderline abstract_t">Lu JL, Sheikh KA, Wu HS, et al. Physiologic-pathologic correlation in Guillain-Barré syndrome in children. Neurology 2000; 54:33.</a></li><li><a class="nounderline abstract_t">Hahn AF. Guillain-Barré syndrome. Lancet 1998; 352:635.</a></li><li><a class="nounderline abstract_t">Asbury AK, Arnason BG, Adams RD. The inflammatory lesion in idiopathic polyneuritis. Its role in pathogenesis. Medicine (Baltimore) 1969; 48:173.</a></li><li><a class="nounderline abstract_t">Prineas JW. Pathology of the Guillain-Barré syndrome. Ann Neurol 1981; 9 Suppl:6.</a></li><li><a class="nounderline abstract_t">Hafer-Macko CE, Sheikh KA, Li CY, et al. Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy. Ann Neurol 1996; 39:625.</a></li><li><a class="nounderline abstract_t">Kieseier BC, Kiefer R, Gold R, et al. Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system. Muscle Nerve 2004; 30:131.</a></li><li><a class="nounderline abstract_t">Hafer-Macko C, Hsieh ST, Li CY, et al. Acute motor axonal neuropathy: an antibody-mediated attack on axolemma. Ann Neurol 1996; 40:635.</a></li><li><a class="nounderline abstract_t">Griffin JW, Li CY, Macko C, et al. Early nodal changes in the acute motor axonal neuropathy pattern of the Guillain-Barré syndrome. J Neurocytol 1996; 25:33.</a></li><li><a class="nounderline abstract_t">Uncini A, Kuwabara S. Nodopathies of the peripheral nerve: an emerging concept. J Neurol Neurosurg Psychiatry 2015; 86:1186.</a></li><li><a class="nounderline abstract_t">Ho TW, Hsieh ST, Nachamkin I, et al. Motor nerve terminal degeneration provides a potential mechanism for rapid recovery in acute motor axonal neuropathy after Campylobacter infection. Neurology 1997; 48:717.</a></li><li><a class="nounderline abstract_t">Yuki N, Susuki K, Koga M, et al. Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain-Barre syndrome. Proc Natl Acad Sci U S A 2004; 101:11404.</a></li><li><a class="nounderline abstract_t">Yuki N, Yamada M, Koga M, et al. Animal model of axonal Guillain-Barré syndrome induced by sensitization with GM1 ganglioside. Ann Neurol 2001; 49:712.</a></li><li><a class="nounderline abstract_t">Yuki N, Kuwabara S. Axonal Guillain-Barré syndrome: carbohydrate mimicry and pathophysiology. J Peripher Nerv Syst 2007; 12:238.</a></li><li><a class="nounderline abstract_t">Jacobs BC, van Doorn PA, Schmitz PI, et al. Campylobacter jejuni infections and anti-GM1 antibodies in Guillain-Barré syndrome. Ann Neurol 1996; 40:181.</a></li><li><a class="nounderline abstract_t">Rees JH, Gregson NA, Hughes RA. Anti-ganglioside GM1 antibodies in Guillain-Barré syndrome and their relationship to Campylobacter jejuni infection. Ann Neurol 1995; 38:809.</a></li><li><a class="nounderline abstract_t">Yuki N, Yoshino H, Sato S, Miyatake T. Acute axonal polyneuropathy associated with anti-GM1 antibodies following Campylobacter enteritis. Neurology 1990; 40:1900.</a></li><li><a class="nounderline abstract_t">Shahrizaila N, Yuki N. Guillain-barré syndrome animal model: the first proof of molecular mimicry in human autoimmune disorder. J Biomed Biotechnol 2011; 2011:829129.</a></li><li><a class="nounderline abstract_t">Rees JH, Soudain SE, Gregson NA, Hughes RA. Campylobacter jejuni infection and Guillain-Barré syndrome. N Engl J Med 1995; 333:1374.</a></li><li><a class="nounderline abstract_t">Ogawara K, Kuwabara S, Mori M, et al. Axonal Guillain-Barré syndrome: relation to anti-ganglioside antibodies and Campylobacter jejuni infection in Japan. Ann Neurol 2000; 48:624.</a></li><li><a class="nounderline abstract_t">Yuki N, Taki T, Inagaki F, et al. A bacterium lipopolysaccharide that elicits Guillain-Barré syndrome has a GM1 ganglioside-like structure. J Exp Med 1993; 178:1771.</a></li><li><a class="nounderline abstract_t">Jacobs BC, Hazenberg MP, van Doorn PA, et al. Cross-reactive antibodies against gangliosides and Campylobacter jejuni lipopolysaccharides in patients with Guillain-Barré or Miller Fisher syndrome. J Infect Dis 1997; 175:729.</a></li><li><a class="nounderline abstract_t">Yuki N, Sato S, Tsuji S, et al. An immunologic abnormality common to Bickerstaff's brain stem encephalitis and Fisher's syndrome. J Neurol Sci 1993; 118:83.</a></li><li><a class="nounderline abstract_t">Koga M, Yoshino H, Morimatsu M, Yuki N. Anti-GT1a IgG in Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 2002; 72:767.</a></li><li><a class="nounderline abstract_t">Wakerley BR, Yuki N. Pharyngeal-cervical-brachial variant of Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry 2014; 85:339.</a></li><li><a class="nounderline abstract_t">Koga M, Takahashi M, Masuda M, et al. Campylobacter gene polymorphism as a determinant of clinical features of Guillain-Barré syndrome. Neurology 2005; 65:1376.</a></li><li><a class="nounderline abstract_t">Hughes RA, Swan AV, Raphaël JC, et al. Immunotherapy for Guillain-Barré syndrome: a systematic review. Brain 2007; 130:2245.</a></li><li><a class="nounderline abstract_t">Lehmann HC, Hartung HP, Kieseier BC, Hughes RA. Guillain-Barré syndrome after exposure to influenza virus. Lancet Infect Dis 2010; 10:643.</a></li><li><a class="nounderline abstract_t">Leonhard SE, van der Eijk AA, Andersen H, et al. An International Perspective on Preceding Infections in Guillain-Barré Syndrome: The IGOS-1000 Cohort. Neurology 2022; 99:e1299.</a></li><li><a class="nounderline abstract_t">Doets AY, Verboon C, van den Berg B, et al. Regional variation of Guillain-Barré syndrome. Brain 2018; 141:2866.</a></li><li><a class="nounderline abstract_t">Hao Y, Wang W, Jacobs BC, et al. Antecedent infections in Guillain-Barré syndrome: a single-center, prospective study. Ann Clin Transl Neurol 2019; 6:2510.</a></li><li><a class="nounderline abstract_t">McCarthy N, Giesecke J. Incidence of Guillain-Barré syndrome following infection with Campylobacter jejuni. Am J Epidemiol 2001; 153:610.</a></li><li><a class="nounderline abstract_t">Lastovica AJ, Goddard EA, Argent AC. Guillain-Barré syndrome in South Africa associated with Campylobacter jejuni O:41 strains. J Infect Dis 1997; 176 Suppl 2:S139.</a></li><li><a class="nounderline abstract_t">Nishimura M, Nukina M, Kuroki S, et al. Characterization of Campylobacter jejuni isolates from patients with Guillain-Barré syndrome. J Neurol Sci 1997; 153:91.</a></li><li><a class="nounderline abstract_t">Griffin JW, Li CY, Ho TW, et al. Pathology of the motor-sensory axonal Guillain-Barré syndrome. Ann Neurol 1996; 39:17.</a></li><li><a class="nounderline abstract_t">Visser LH, Van der Meché FG, Van Doorn PA, et al. Guillain-Barré syndrome without sensory loss (acute motor neuropathy). A subgroup with specific clinical, electrodiagnostic and laboratory features. Dutch Guillain-Barré Study Group. Brain 1995; 118 ( Pt 4):841.</a></li><li><a class="nounderline abstract_t">Stowe J, Andrews N, Wise L, Miller E. Investigation of the temporal association of Guillain-Barre syndrome with influenza vaccine and influenzalike illness using the United Kingdom General Practice Research Database. Am J Epidemiol 2009; 169:382.</a></li><li><a class="nounderline abstract_t">Tam CC, O'Brien SJ, Petersen I, et al. Guillain-Barré syndrome and preceding infection with campylobacter, influenza and Epstein-Barr virus in the general practice research database. PLoS One 2007; 2:e344.</a></li><li><a class="nounderline abstract_t">Tam CC, O'Brien SJ, Rodrigues LC. Influenza, Campylobacter and Mycoplasma infections, and hospital admissions for Guillain-Barré syndrome, England. Emerg Infect Dis 2006; 12:1880.</a></li><li><a class="nounderline abstract_t">Vellozzi C, Iqbal S, Broder K. Guillain-Barre syndrome, influenza, and influenza vaccination: the epidemiologic evidence. Clin Infect Dis 2014; 58:1149.</a></li><li><a class="nounderline abstract_t">Orlikowski D, Porcher R, Sivadon-Tardy V, et al. Guillain-Barré syndrome following primary cytomegalovirus infection: a prospective cohort study. Clin Infect Dis 2011; 52:837.</a></li><li><a class="nounderline abstract_t">Steininger C, Popow-Kraupp T, Seiser A, et al. Presence of cytomegalovirus in cerebrospinal fluid of patients with Guillain-Barre syndrome. J Infect Dis 2004; 189:984.</a></li><li><a class="nounderline abstract_t">Winer JB, Hughes RA, Anderson MJ, et al. A prospective study of acute idiopathic neuropathy. II. Antecedent events. J Neurol Neurosurg Psychiatry 1988; 51:613.</a></li><li><a class="nounderline abstract_t">Jacobs BC, Rothbarth PH, van der Meché FG, et al. The spectrum of antecedent infections in Guillain-Barré syndrome: a case-control study. Neurology 1998; 51:1110.</a></li><li><a class="nounderline abstract_t">Sivadon-Tardy V, Orlikowski D, Porcher R, et al. Guillain-Barré syndrome and influenza virus infection. Clin Infect Dis 2009; 48:48.</a></li><li><a class="nounderline abstract_t">Brannagan TH 3rd, Zhou Y. HIV-associated Guillain-Barré syndrome. J Neurol Sci 2003; 208:39.</a></li><li><a class="nounderline abstract_t">Piliero PJ, Fish DG, Preston S, et al. Guillain-Barré syndrome associated with immune reconstitution. Clin Infect Dis 2003; 36:e111.</a></li><li><a class="nounderline abstract_t">Toscano G, Palmerini F, Ravaglia S, et al. Guillain-Barré Syndrome Associated with SARS-CoV-2. N Engl J Med 2020; 382:2574.</a></li><li><a class="nounderline abstract_t">Zhao H, Shen D, Zhou H, et al. Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence? Lancet Neurol 2020; 19:383.</a></li><li><a class="nounderline abstract_t">Aladawi M, Elfil M, Abu-Esheh B, et al. Guillain Barre Syndrome as a Complication of COVID-19: A Systematic Review. Can J Neurol Sci 2022; 49:38.</a></li><li><a class="nounderline abstract_t">Bishara H, Arbel A, Barnett-Griness O, et al. Association Between Guillain-Barré Syndrome and COVID-19 Infection and Vaccination: A Population-Based Nested Case-Control Study. Neurology 2023; 101:e2035.</a></li><li><a class="nounderline abstract_t">Hasan I, Saif-Ur-Rahman KM, Hayat S, et al. Guillain-Barré syndrome associated with SARS-CoV-2 infection: A systematic review and individual participant data meta-analysis. J Peripher Nerv Syst 2020; 25:335.</a></li><li><a class="nounderline abstract_t">Pimentel V, Luchsinger VW, Carvalho GL, et al. Guillain-Barré syndrome associated with COVID-19: A systematic review. Brain Behav Immun Health 2023; 28:100578.</a></li><li><a class="nounderline abstract_t">Geurtsvankessel CH, Islam Z, Mohammad QD, et al. Hepatitis E and Guillain-Barre syndrome. Clin Infect Dis 2013; 57:1369.</a></li><li><a class="nounderline abstract_t">Kamar N, Bendall RP, Peron JM, et al. Hepatitis E virus and neurologic disorders. Emerg Infect Dis 2011; 17:173.</a></li><li><a class="nounderline abstract_t">Meyer Sauteur PM, Huizinga R, Tio-Gillen AP, et al. Mycoplasma pneumoniae triggering the Guillain-Barré syndrome: A case-control study. Ann Neurol 2016; 80:566.</a></li><li><a class="nounderline abstract_t">Mori M, Kuwabara S, Miyake M, et al. Haemophilus influenzae infection and Guillain-Barré syndrome. Brain 2000; 123 ( Pt 10):2171.</a></li><li><a class="nounderline abstract_t">Stegmann-Planchard S, Gallian P, Tressières B, et al. Chikungunya, a Risk Factor for Guillain-Barré Syndrome. Clin Infect Dis 2020; 70:1233.</a></li><li><a class="nounderline abstract_t">Wang G, Li H, Yang X, et al. Guillain-Barré Syndrome Associated with JEV Infection. N Engl J Med 2020; 383:1188.</a></li><li><a class="nounderline abstract_t">Lasky T, Terracciano GJ, Magder L, et al. The Guillain-Barré syndrome and the 1992-1993 and 1993-1994 influenza vaccines. N Engl J Med 1998; 339:1797.</a></li><li><a class="nounderline abstract_t">Baxter R, Bakshi N, Fireman B, et al. Lack of association of Guillain-Barré syndrome with vaccinations. Clin Infect Dis 2013; 57:197.</a></li><li><a class="nounderline abstract_t">Hughes RA, Charlton J, Latinovic R, Gulliford MC. No association between immunization and Guillain-Barré syndrome in the United Kingdom, 1992 to 2000. Arch Intern Med 2006; 166:1301.</a></li><li><a class="nounderline abstract_t">Greene SK, Rett MD, Vellozzi C, et al. Guillain-Barré Syndrome, Influenza Vaccination, and Antecedent Respiratory and Gastrointestinal Infections: A Case-Centered Analysis in the Vaccine Safety Datalink, 2009-2011. PLoS One 2013; 8:e67185.</a></li><li><a class="nounderline abstract_t">Kwong JC, Vasa PP, Campitelli MA, et al. Risk of Guillain-Barré syndrome after seasonal influenza vaccination and influenza health-care encounters: a self-controlled study. Lancet Infect Dis 2013; 13:769.</a></li><li><a class="nounderline abstract_t">Baxter R, Lewis N, Bakshi N, et al. Recurrent Guillain-Barre syndrome following vaccination. Clin Infect Dis 2012; 54:800.</a></li><li><a class="nounderline abstract_t">Kuitwaard K, Bos-Eyssen ME, Blomkwist-Markens PH, van Doorn PA. Recurrences, vaccinations and long-term symptoms in GBS and CIDP. J Peripher Nerv Syst 2009; 14:310.</a></li><li><a class="nounderline abstract_t">Salmon DA, Proschan M, Forshee R, et al. Association between Guillain-Barré syndrome and influenza A (H1N1) 2009 monovalent inactivated vaccines in the USA: a meta-analysis. Lancet 2013; 381:1461.</a></li><li><a class="nounderline abstract_t">De Wals P, Deceuninck G, Toth E, et al. Risk of Guillain-Barré syndrome following H1N1 influenza vaccination in Quebec. JAMA 2012; 308:175.</a></li><li><a class="nounderline abstract_t">Petráš M, Lesná IK, Dáňová J, Čelko AM. Is an Increased Risk of Developing Guillain-Barré Syndrome Associated with Seasonal Influenza Vaccination? A Systematic Review and Meta-Analysis. Vaccines (Basel) 2020; 8.</a></li><li><a class="nounderline abstract_t">Romio S, Weibel D, Dieleman JP, et al. Guillain-Barré syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccines: a multinational self-controlled case series in Europe. PLoS One 2014; 9:e82222.</a></li><li><a class="nounderline abstract_t">Soni R, Heindl SE, Wiltshire DA, et al. Antigenic Variability a Potential Factor in Assessing Relationship Between Guillain Barré Syndrome and Influenza Vaccine - Up to Date Literature Review. Cureus 2020; 12:e10208.</a></li><li><a class="nounderline abstract_t">Martín Arias LH, Sanz R, Sáinz M, et al. Guillain-Barré syndrome and influenza vaccines: A meta-analysis. Vaccine 2015; 33:3773.</a></li><li class="breakAll">Guillain-Barre syndrome common concerns. http://www.cdc.gov/vaccinesafety/Concerns/gbs.html (Accessed on August 15, 2019).</li><li><a class="nounderline abstract_t">Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barré syndrome. Lancet 2016; 388:717.</a></li><li class="breakAll">https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-requires-warning-about-guillain-barre-syndrome-gbs-be-included-prescribing-information-shingrix (Accessed on March 26, 2021).</li><li class="breakAll">U.S. FDA COVID-19 Update: July 13, 2021 https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-july-13-2021.</li><li class="breakAll">European Medicines Agency COVID-19 vaccine safety update 14 July 2021 ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-covid-19-vaccine-janssen-14-july-2021_en.pdf.</li><li><a class="nounderline abstract_t">Allen CM, Ramsamy S, Tarr AW, et al. Guillain-Barré Syndrome Variant Occurring after SARS-CoV-2 Vaccination. Ann Neurol 2021; 90:315.</a></li><li><a class="nounderline abstract_t">Maramattom BV, Krishnan P, Paul R, et al. Guillain-Barré Syndrome following ChAdOx1-S/nCoV-19 Vaccine. Ann Neurol 2021; 90:312.</a></li><li><a class="nounderline abstract_t">Woo EJ, Mba-Jonas A, Dimova RB, et al. Association of Receipt of the Ad26.COV2.S COVID-19 Vaccine With Presumptive Guillain-Barré Syndrome, February-July 2021. JAMA 2021; 326:1606.</a></li><li><a class="nounderline abstract_t">Abara WE, Gee J, Marquez P, et al. Reports of Guillain-Barré Syndrome After COVID-19 Vaccination in the United States. JAMA Netw Open 2023; 6:e2253845.</a></li><li><a class="nounderline abstract_t">Hanson KE, Goddard K, Lewis N, et al. Incidence of Guillain-Barré Syndrome After COVID-19 Vaccination in the Vaccine Safety Datalink. JAMA Netw Open 2022; 5:e228879.</a></li><li><a class="nounderline abstract_t">Keh RYS, Scanlon S, Datta-Nemdharry P, et al. COVID-19 vaccination and Guillain-Barré syndrome: analyses using the National Immunoglobulin Database. Brain 2023; 146:739.</a></li><li><a class="nounderline abstract_t">Le Vu S, Bertrand M, Botton J, et al. Risk of Guillain-Barré Syndrome Following COVID-19 Vaccines: A Nationwide Self-Controlled Case Series Study. Neurology 2023; 101:e2094.</a></li><li class="breakAll">Ropper AH, Wijdicks EFM, Truax BT. Guillain-Barré syndrome, FA Davis, 1991. p.57.</li><li><a class="nounderline abstract_t">Rudant J, Dupont A, Mikaeloff Y, et al. Surgery and risk of Guillain-Barré syndrome: A French nationwide epidemiologic study. Neurology 2018; 91:e1220.</a></li><li><a class="nounderline abstract_t">Ropper AH. The Guillain-Barré syndrome. N Engl J Med 1992; 326:1130.</a></li><li><a class="nounderline abstract_t">Chan LY, Tsui MH, Leung TN. Guillain-Barré syndrome in pregnancy. Acta Obstet Gynecol Scand 2004; 83:319.</a></li><li><a class="nounderline abstract_t">Shin IS, Baer AN, Kwon HJ, et al. Guillain-Barré and Miller Fisher syndromes occurring with tumor necrosis factor alpha antagonist therapy. Arthritis Rheum 2006; 54:1429.</a></li><li><a class="nounderline abstract_t">Peltier AC, Russell JW. Recent advances in drug-induced neuropathies. Curr Opin Neurol 2002; 15:633.</a></li><li><a class="nounderline abstract_t">Pritchard J, Appleton R, Howard R, Hughes RA. Guillain-Barré syndrome seen in users of isotretinoin. BMJ 2004; 328:1537.</a></li><li><a class="nounderline abstract_t">de Maleissye MF, Nicolas G, Saiag P. Pembrolizumab-Induced Demyelinating Polyradiculoneuropathy. N Engl J Med 2016; 375:296.</a></li><li><a class="nounderline abstract_t">Möhn N, Beutel G, Gutzmer R, et al. Neurological Immune Related Adverse Events Associated with Nivolumab, Ipilimumab, and Pembrolizumab Therapy-Review of the Literature and Future Outlook. J Clin Med 2019; 8.</a></li><li><a class="nounderline abstract_t">Ong S, Chapman J, Young G, Mansy T. Guillain-Barré-like syndrome during pembrolizumab treatment. Muscle Nerve 2018.</a></li><li><a class="nounderline abstract_t">Fargeot G, Dupel-Pottier C, Stephant M, et al. Brentuximab vedotin treatment associated with acute and chronic inflammatory demyelinating polyradiculoneuropathies. J Neurol Neurosurg Psychiatry 2020; 91:786.</a></li><li><a class="nounderline abstract_t">McGrogan A, Madle GC, Seaman HE, de Vries CS. The epidemiology of Guillain-Barré syndrome worldwide. A systematic literature review. Neuroepidemiology 2009; 32:150.</a></li><li><a class="nounderline abstract_t">Sejvar JJ, Baughman AL, Wise M, Morgan OW. Population incidence of Guillain-Barré syndrome: a systematic review and meta-analysis. Neuroepidemiology 2011; 36:123.</a></li><li><a class="nounderline abstract_t">Fokke C, van den Berg B, Drenthen J, et al. Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria. Brain 2014; 137:33.</a></li><li><a class="nounderline abstract_t">Leonhard SE, Mandarakas MR, Gondim FAA, et al. Diagnosis and management of Guillain-Barré syndrome in ten steps. Nat Rev Neurol 2019; 15:671.</a></li><li><a class="nounderline abstract_t">Alshekhlee A, Hussain Z, Sultan B, Katirji B. Guillain-Barré syndrome: incidence and mortality rates in US hospitals. Neurology 2008; 70:1608.</a></li><li><a class="nounderline abstract_t">Uncini A, Notturno F, Kuwabara S. Hyper-reflexia in Guillain-Barré syndrome: systematic review. J Neurol Neurosurg Psychiatry 2020; 91:278.</a></li><li><a class="nounderline abstract_t">Yuki N, Kokubun N, Kuwabara S, et al. Guillain-Barré syndrome associated with normal or exaggerated tendon reflexes. J Neurol 2012; 259:1181.</a></li><li><a class="nounderline abstract_t">Moulin DE, Hagen N, Feasby TE, et al. Pain in Guillain-Barré syndrome. Neurology 1997; 48:328.</a></li><li><a class="nounderline abstract_t">Ruts L, Drenthen J, Jongen JL, et al. Pain in Guillain-Barre syndrome: a long-term follow-up study. Neurology 2010; 75:1439.</a></li><li><a class="nounderline abstract_t">Flachenecker P. Autonomic dysfunction in Guillain-Barré syndrome and multiple sclerosis. J Neurol 2007; 254 Suppl 2:II96.</a></li><li><a class="nounderline abstract_t">Chakraborty T, Kramer CL, Wijdicks EFM, Rabinstein AA. Dysautonomia in Guillain-Barré Syndrome: Prevalence, Clinical Spectrum, and Outcomes. Neurocrit Care 2020; 32:113.</a></li><li><a class="nounderline abstract_t">Zochodne DW. Autonomic involvement in Guillain-Barré syndrome: a review. Muscle Nerve 1994; 17:1145.</a></li><li><a class="nounderline abstract_t">Anandan C, Khuder SA, Koffman BM. Prevalence of autonomic dysfunction in hospitalized patients with Guillain-Barré syndrome. Muscle Nerve 2017; 56:331.</a></li><li><a class="nounderline abstract_t">Hoffmann O, Reuter U, Schielke E, Weber JR. SIADH as the first symptom of Guillain-Barré syndrome. Neurology 1999; 53:1365.</a></li><li><a class="nounderline abstract_t">Saifudheen K, Jose J, Gafoor VA, Musthafa M. Guillain-Barre syndrome and SIADH. Neurology 2011; 76:701.</a></li><li><a class="nounderline abstract_t">Bavikatte G, Gaber T, Eshiett MU. Posterior reversible encephalopathy syndrome as a complication of Guillain-Barré syndrome. J Clin Neurosci 2010; 17:924.</a></li><li><a class="nounderline abstract_t">Elahi A, Kelkar P, St Louis EK. Posterior reversible encephalopathy syndrome as the initial manifestation of Guillain-Barré Syndrome. Neurocrit Care 2004; 1:465.</a></li><li><a class="nounderline abstract_t">Etxeberria A, Lonneville S, Rutgers MP, Gille M. Posterior reversible encephalopathy syndrome as a revealing manifestation of Guillain-Barré syndrome. Rev Neurol (Paris) 2012; 168:283.</a></li><li><a class="nounderline abstract_t">McKhann GM, Cornblath DR, Griffin JW, et al. Acute motor axonal neuropathy: a frequent cause of acute flaccid paralysis in China. Ann Neurol 1993; 33:333.</a></li><li><a class="nounderline abstract_t">Feasby TE, Gilbert JJ, Brown WF, et al. An acute axonal form of Guillain-Barré polyneuropathy. Brain 1986; 109 ( Pt 6):1115.</a></li><li><a class="nounderline abstract_t">Ye Y, Wang K, Deng F, Xing Y. Electrophysiological subtypes and prognosis of Guillain-Barré syndrome in northeastern China. Muscle Nerve 2013; 47:68.</a></li><li><a class="nounderline abstract_t">Ho TW, Mishu B, Li CY, et al. Guillain-Barré syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain 1995; 118 ( Pt 3):597.</a></li><li><a class="nounderline abstract_t">Susuki K, Yuki N, Schafer DP, et al. Dysfunction of nodes of Ranvier: a mechanism for anti-ganglioside antibody-mediated neuropathies. Exp Neurol 2012; 233:534.</a></li><li class="breakAll">Rocha Cabrero F, Morrison EH. Miller Fisher Syndrome. In: StatPearls, StatPearls Publishing, 2020.</li><li><a class="nounderline abstract_t">Shahrizaila N, Yuki N. Bickerstaff brainstem encephalitis and Fisher syndrome: anti-GQ1b antibody syndrome. J Neurol Neurosurg Psychiatry 2013; 84:576.</a></li><li><a class="nounderline abstract_t">Phillips MS, Stewart S, Anderson JR. Neuropathological findings in Miller Fisher syndrome. J Neurol Neurosurg Psychiatry 1984; 47:492.</a></li><li><a class="nounderline abstract_t">FISHER M. An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia). N Engl J Med 1956; 255:57.</a></li><li><a class="nounderline abstract_t">Lo YL. Clinical and immunological spectrum of the Miller Fisher syndrome. Muscle Nerve 2007; 36:615.</a></li><li><a class="nounderline abstract_t">Lee SH, Lim GH, Kim JS, et al. Acute ophthalmoplegia (without ataxia) associated with anti-GQ1b antibody. Neurology 2008; 71:426.</a></li><li><a class="nounderline abstract_t">Kaymakamzade B, Selcuk F, Koysuren A, et al. Pupillary Involvement in Miller Fisher Syndrome. Neuroophthalmology 2013; 37:111.</a></li><li><a class="nounderline abstract_t">Chiba A, Kusunoki S, Obata H, et al. Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barré syndrome: clinical and immunohistochemical studies. Neurology 1993; 43:1911.</a></li><li><a class="nounderline abstract_t">Willison HJ, Veitch J, Paterson G, Kennedy PG. Miller Fisher syndrome is associated with serum antibodies to GQ1b ganglioside. J Neurol Neurosurg Psychiatry 1993; 56:204.</a></li><li><a class="nounderline abstract_t">Fross RD, Daube JR. Neuropathy in the Miller Fisher syndrome: clinical and electrophysiologic findings. Neurology 1987; 37:1493.</a></li><li><a class="nounderline abstract_t">Odaka M, Yuki N, Yamada M, et al. Bickerstaff's brainstem encephalitis: clinical features of 62 cases and a subgroup associated with Guillain-Barré syndrome. Brain 2003; 126:2279.</a></li><li><a class="nounderline abstract_t">Odaka M, Yuki N, Hirata K. Anti-GQ1b IgG antibody syndrome: clinical and immunological range. J Neurol Neurosurg Psychiatry 2001; 70:50.</a></li><li><a class="nounderline abstract_t">Winer JB. Bickerstaff's encephalitis and the Miller Fisher syndrome. J Neurol Neurosurg Psychiatry 2001; 71:433.</a></li><li><a class="nounderline abstract_t">Alberti MA, Povedano M, Montero J, Casasnovas C. Early electrophysiological findings in Fisher-Bickerstaff syndrome. Neurologia (Engl Ed) 2020; 35:40.</a></li><li><a class="nounderline abstract_t">Nagashima T, Koga M, Odaka M, et al. Continuous spectrum of pharyngeal-cervical-brachial variant of Guillain-Barré syndrome. Arch Neurol 2007; 64:1519.</a></li><li><a class="nounderline abstract_t">Ropper AH. Unusual clinical variants and signs in Guillain-Barré syndrome. Arch Neurol 1986; 43:1150.</a></li><li><a class="nounderline abstract_t">Ropper AH. Further regional variants of acute immune polyneuropathy. Bifacial weakness or sixth nerve paresis with paresthesias, lumbar polyradiculopathy, and ataxia with pharyngeal-cervical-brachial weakness. Arch Neurol 1994; 51:671.</a></li><li><a class="nounderline abstract_t">Miura Y, Susuki K, Yuki N, et al. Guillain-barré syndrome presenting pharyngeal-cervical-brachial weakness in the recovery phase. Eur Neurol 2002; 48:53.</a></li><li><a class="nounderline abstract_t">van den Berg B, Fokke C, Drenthen J, et al. Paraparetic Guillain-Barré syndrome. Neurology 2014; 82:1984.</a></li><li><a class="nounderline abstract_t">Koike H, Atsuta N, Adachi H, et al. Clinicopathological features of acute autonomic and sensory neuropathy. Brain 2010; 133:2881.</a></li><li><a class="nounderline abstract_t">Mericle RA, Triggs WJ. Treatment of acute pandysautonomia with intravenous immunoglobulin. J Neurol Neurosurg Psychiatry 1997; 62:529.</a></li><li><a class="nounderline abstract_t">Uncini A, Yuki N. Sensory Guillain-Barré syndrome and related disorders: an attempt at systematization. Muscle Nerve 2012; 45:464.</a></li><li><a class="nounderline abstract_t">Wicklein EM, Pfeiffer G, Yuki N, et al. Prominent sensory ataxia in Guillain-Barré syndrome associated with IgG anti-GD1b antibody. J Neurol Sci 1997; 151:227.</a></li><li><a class="nounderline abstract_t">Susuki K, Koga M, Hirata K, et al. A Guillain-Barré syndrome variant with prominent facial diplegia. J Neurol 2009; 256:1899.</a></li><li><a class="nounderline abstract_t">Wakerley BR, Yuki N. Isolated facial diplegia in Guillain-Barré syndrome: Bifacial weakness with paresthesias. Muscle Nerve 2015; 52:927.</a></li><li><a class="nounderline abstract_t">Kim JK, Kim BJ, Shin HY, et al. Acute bulbar palsy as a variant of Guillain-Barré syndrome. Neurology 2016; 86:742.</a></li><li><a class="nounderline abstract_t">van den Berg B, Walgaard C, Drenthen J, et al. Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol 2014; 10:469.</a></li><li><a class="nounderline abstract_t">Criteria for diagnosis of Guillain-Barré syndrome. Ann Neurol 1978; 3:565.</a></li><li><a class="nounderline abstract_t">Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol 1990; 27 Suppl:S21.</a></li><li><a class="nounderline abstract_t">Govoni V, Granieri E, Tola MR, et al. The frequency of clinical variants of Guillain-Barré syndrome in Ferrara, Italy. J Neurol 1999; 246:1010.</a></li><li class="breakAll">World Health Organization. Identification and management of Guillain-Barré syndrome in the context of Zika virus. https://apps.who.int/iris/bitstream/handle/10665/204474/WHO_ZIKV_MOC_16.4_eng.pdf (Accessed on December 06, 2020).</li><li><a class="nounderline abstract_t">Nishimoto Y, Odaka M, Hirata K, Yuki N. Usefulness of anti-GQ1b IgG antibody testing in Fisher syndrome compared with cerebrospinal fluid examination. J Neuroimmunol 2004; 148:200.</a></li><li><a class="nounderline abstract_t">Wong AH, Umapathi T, Nishimoto Y, et al. Cytoalbuminologic dissociation in Asian patients with Guillain-Barré and Miller Fisher syndromes. J Peripher Nerv Syst 2015; 20:47.</a></li><li><a class="nounderline abstract_t">Al-Hakem H, Doets AY, Stino AM, et al. CSF Findings in Relation to Clinical Characteristics, Subtype, and Disease Course in Patients With Guillain-Barré Syndrome. Neurology 2023; 100:e2386.</a></li><li><a class="nounderline abstract_t">Hadden RD, Cornblath DR, Hughes RA, et al. Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Ann Neurol 1998; 44:780.</a></li><li><a class="nounderline abstract_t">Gordon PH, Wilbourn AJ. Early electrodiagnostic findings in Guillain-Barré syndrome. Arch Neurol 2001; 58:913.</a></li><li><a class="nounderline abstract_t">Kimura J. Proximal versus distal slowing of motor nerve conduction velocity in the Guillain-Barré syndrome. Ann Neurol 1978; 3:344.</a></li><li><a class="nounderline abstract_t">Albers JW, Donofrio PD, McGonagle TK. Sequential electrodiagnostic abnormalities in acute inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 1985; 8:528.</a></li><li><a class="nounderline abstract_t">Sumner AJ. The physiological basis for symptoms in Guillain-Barré syndrome. Ann Neurol 1981; 9 Suppl:28.</a></li><li><a class="nounderline abstract_t">Donofrio PD. Guillain-Barré Syndrome. Continuum (Minneap Minn) 2017; 23:1295.</a></li><li><a class="nounderline abstract_t">Kokubun N, Nishibayashi M, Uncini A, et al. Conduction block in acute motor axonal neuropathy. Brain 2010; 133:2897.</a></li><li><a class="nounderline abstract_t">Ho TW, Li CY, Cornblath DR, et al. Patterns of recovery in the Guillain-Barre syndromes. Neurology 1997; 48:695.</a></li><li><a class="nounderline abstract_t">Kuwabara S, Yuki N, Koga M, et al. IgG anti-GM1 antibody is associated with reversible conduction failure and axonal degeneration in Guillain-Barré syndrome. Ann Neurol 1998; 44:202.</a></li><li><a class="nounderline abstract_t">Sekiguchi Y, Uncini A, Yuki N, et al. Antiganglioside antibodies are associated with axonal Guillain-Barré syndrome: a Japanese-Italian collaborative study. J Neurol Neurosurg Psychiatry 2012; 83:23.</a></li><li><a class="nounderline abstract_t">Shang P, Zhu M, Wang Y, et al. Axonal variants of Guillain-Barré syndrome: an update. J Neurol 2021; 268:2402.</a></li><li><a class="nounderline abstract_t">Uncini A, Manzoli C, Notturno F, Capasso M. Pitfalls in electrodiagnosis of Guillain-Barré syndrome subtypes. J Neurol Neurosurg Psychiatry 2010; 81:1157.</a></li><li><a class="nounderline abstract_t">Goodfellow JA, Willison HJ. Guillain-Barré syndrome: a century of progress. Nat Rev Neurol 2016; 12:723.</a></li><li><a class="nounderline abstract_t">Kaida K, Sonoo M, Ogawa G, et al. GM1/GalNAc-GD1a complex: a target for pure motor Guillain-Barre syndrome. Neurology 2008; 71:1683.</a></li><li><a class="nounderline abstract_t">Mantero V, Basilico P, Borelli P, et al. A case of monofocal motor neuropathy with GM1 and GD1b antibodies improved with intravenous immunoglobulin. J Neuroimmunol 2020; 350:577452.</a></li><li><a class="nounderline abstract_t">Lunn M, Hughes R. The relationship between cytomegalovirus infection and Guillain-Barré syndrome. Clin Infect Dis 2011; 52:845.</a></li><li><a class="nounderline abstract_t">Silva CT, Silva S, Silva MJ, et al. Guillain-Barré Syndrome in a Teenage Girl: A Severe Case With Anti-GM2 Antibodies Associated With Acute CMV Infection and Literature Review. Clin Pediatr (Phila) 2020; 59:300.</a></li><li><a class="nounderline abstract_t">Byun WM, Park WK, Park BH, et al. Guillain-Barré syndrome: MR imaging findings of the spine in eight patients. Radiology 1998; 208:137.</a></li><li><a class="nounderline abstract_t">Fontes CA, Dos Santos AA, Marchiori E. Magnetic resonance imaging findings in Guillain-Barré syndrome caused by Zika virus infection. Neuroradiology 2016; 58:837.</a></li><li><a class="nounderline abstract_t">Hattori M, Takada K, Yamada K, et al. [A case of Miller Fisher syndrome with gadolinium-enhancing lesions in the cranial nerves and the cauda equina on magnetic resonance imaging]. Rinsho Shinkeigaku 1999; 39:1054.</a></li><li><a class="nounderline abstract_t">Inoue N, Ichimura H, Goto S, et al. MR imaging findings of spinal posterior column involvement in a case of Miller Fisher syndrome. AJNR Am J Neuroradiol 2004; 25:645.</a></li><li><a class="nounderline abstract_t">Nagaoka U, Kato T, Kurita K, et al. Cranial nerve enhancement on three-dimensional MRI in Miller Fisher syndrome. Neurology 1996; 47:1601.</a></li><li><a class="nounderline abstract_t">Gallardo E, Sedano MJ, Orizaola P, et al. Spinal nerve involvement in early Guillain-Barré syndrome: a clinico-electrophysiological, ultrasonographic and pathological study. Clin Neurophysiol 2015; 126:810.</a></li><li><a class="nounderline abstract_t">Grimm A, Décard BF, Axer H. Ultrasonography of the peripheral nervous system in the early stage of Guillain-Barré syndrome. J Peripher Nerv Syst 2014; 19:234.</a></li><li><a class="nounderline abstract_t">Razali SNO, Arumugam T, Yuki N, et al. Serial peripheral nerve ultrasound in Guillain-Barré syndrome. Clin Neurophysiol 2016; 127:1652.</a></li><li><a class="nounderline abstract_t">Grimm A, Oertl H, Auffenberg E, et al. Differentiation Between Guillain-Barré Syndrome and Acute-Onset Chronic Inflammatory Demyelinating Polyradiculoneuritis-a Prospective Follow-up Study Using Ultrasound and Neurophysiological Measurements. Neurotherapeutics 2019; 16:838.</a></li><li><a class="nounderline abstract_t">Ruts L, Drenthen J, Jacobs BC, et al. Distinguishing acute-onset CIDP from fluctuating Guillain-Barre syndrome: a prospective study. Neurology 2010; 74:1680.</a></li><li><a class="nounderline abstract_t">Lee SU, Kim HJ, Choi JY, et al. Acute vestibular syndrome associated with anti-GQ1b antibody. Neurology 2019; 93:e1085.</a></li></ol></div><div id="topicVersionRevision">Topic 5137 Version 40.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22694000" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Guillain-Barrésyndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33647239" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Guillain-Barrésyndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10636122" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Physiologic-pathologic correlation in Guillain-Barrésyndrome in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9746040" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Guillain-Barrésyndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5769741" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The inflammatory lesion in idiopathic polyneuritis. Its role in pathogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7224616" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Pathology of the Guillain-Barrésyndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8619548" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15266629" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8871584" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Acute motor axonal neuropathy: an antibody-mediated attack on axolemma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8852937" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Early nodal changes in the acute motor axonal neuropathy pattern of the Guillain-Barrésyndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25699569" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Nodopathies of the peripheral nerve: an emerging concept.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9065554" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Motor nerve terminal degeneration provides a potential mechanism for rapid recovery in acute motor axonal neuropathy after Campylobacter infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15277677" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain-Barre syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11409422" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Animal model of axonal Guillain-Barrésyndrome induced by sensitization with GM1 ganglioside.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18042134" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Axonal Guillain-Barrésyndrome: carbohydrate mimicry and pathophysiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8773599" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Campylobacter jejuni infections and anti-GM1 antibodies in Guillain-Barrésyndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7486873" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Anti-ganglioside GM1 antibodies in Guillain-Barrésyndrome and their relationship to Campylobacter jejuni infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2247243" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Acute axonal polyneuropathy associated with anti-GM1 antibodies following Campylobacter enteritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21197269" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Guillain-barrésyndrome animal model: the first proof of molecular mimicry in human autoimmune disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7477117" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Campylobacter jejuni infection and Guillain-Barrésyndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11026446" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Axonal Guillain-Barrésyndrome: relation to anti-ganglioside antibodies and Campylobacter jejuni infection in Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8228822" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : A bacterium lipopolysaccharide that elicits Guillain-Barrésyndrome has a GM1 ganglioside-like structure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9041356" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Cross-reactive antibodies against gangliosides and Campylobacter jejuni lipopolysaccharides in patients with Guillain-Barréor Miller Fisher syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8229054" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : An immunologic abnormality common to Bickerstaff's brain stem encephalitis and Fisher's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12023422" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Anti-GT1a IgG in Guillain-Barrésyndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23804237" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Pharyngeal-cervical-brachial variant of Guillain-Barre syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16162859" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Campylobacter gene polymorphism as a determinant of clinical features of Guillain-Barrésyndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17337484" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Immunotherapy for Guillain-Barrésyndrome: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20797646" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Guillain-Barrésyndrome after exposure to influenza virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35981895" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : An International Perspective on Preceding Infections in Guillain-BarréSyndrome: The IGOS-1000 Cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30247567" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Regional variation of Guillain-Barrésyndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31714025" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Antecedent infections in Guillain-Barrésyndrome: a single-center, prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11257070" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Incidence of Guillain-Barrésyndrome following infection with Campylobacter jejuni.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9396698" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Guillain-Barrésyndrome in South Africa associated with Campylobacter jejuni O:41 strains.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9455985" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Characterization of Campylobacter jejuni isolates from patients with Guillain-Barrésyndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8572662" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Pathology of the motor-sensory axonal Guillain-Barrésyndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7655882" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Guillain-Barrésyndrome without sensory loss (acute motor neuropathy). A subgroup with specific clinical, electrodiagnostic and laboratory features. Dutch Guillain-BarréStudy Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19033158" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Investigation of the temporal association of Guillain-Barre syndrome with influenza vaccine and influenzalike illness using the United Kingdom General Practice Research Database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17406668" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Guillain-Barrésyndrome and preceding infection with campylobacter, influenza and Epstein-Barr virus in the general practice research database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17326939" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Influenza, Campylobacter and Mycoplasma infections, and hospital admissions for Guillain-Barrésyndrome, England.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24415636" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Guillain-Barre syndrome, influenza, and influenza vaccination: the epidemiologic evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21427390" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Guillain-Barrésyndrome following primary cytomegalovirus infection: a prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14999600" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Presence of cytomegalovirus in cerebrospinal fluid of patients with Guillain-Barre syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3404161" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : A prospective study of acute idiopathic neuropathy. II. Antecedent events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9781538" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : The spectrum of antecedent infections in Guillain-Barrésyndrome: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19025491" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Guillain-Barrésyndrome and influenza virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12639723" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : HIV-associated Guillain-Barrésyndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12715328" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Guillain-Barrésyndrome associated with immune reconstitution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32302082" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Guillain-BarréSyndrome Associated with SARS-CoV-2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32246917" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Guillain-Barrésyndrome associated with SARS-CoV-2 infection: causality or coincidence?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33949300" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Guillain Barre Syndrome as a Complication of COVID-19: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37852786" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Association Between Guillain-BarréSyndrome and COVID-19 Infection and Vaccination: A Population-Based Nested Case-Control Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33112450" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Guillain-Barrésyndrome associated with SARS-CoV-2 infection: A systematic review and individual participant data meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36686624" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Guillain-Barrésyndrome associated with COVID-19: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23899686" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Hepatitis E and Guillain-Barre syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21291585" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Hepatitis E virus and neurologic disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27490360" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Mycoplasma pneumoniae triggering the Guillain-Barrésyndrome: A case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11004133" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Haemophilus influenzae infection and Guillain-Barrésyndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31290540" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Chikungunya, a Risk Factor for Guillain-BarréSyndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32937054" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Guillain-BarréSyndrome Associated with JEV Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9854114" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : The Guillain-Barrésyndrome and the 1992-1993 and 1993-1994 influenza vaccines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23580737" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Lack of association of Guillain-Barrésyndrome with vaccinations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16801513" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : No association between immunization and Guillain-Barrésyndrome in the United Kingdom, 1992 to 2000.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23840621" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Guillain-BarréSyndrome, Influenza Vaccination, and Antecedent Respiratory and Gastrointestinal Infections: A Case-Centered Analysis in the Vaccine Safety Datalink, 2009-2011.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23810252" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Risk of Guillain-Barrésyndrome after seasonal influenza vaccination and influenza health-care encounters: a self-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22267712" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Recurrent Guillain-Barre syndrome following vaccination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20021573" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Recurrences, vaccinations and long-term symptoms in GBS and CIDP.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23498095" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Association between Guillain-Barrésyndrome and influenza A (H1N1) 2009 monovalent inactivated vaccines in the USA: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22782419" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Risk of Guillain-Barrésyndrome following H1N1 influenza vaccination in Quebec.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32230964" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Is an Increased Risk of Developing Guillain-BarréSyndrome Associated with Seasonal Influenza Vaccination? A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24404128" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Guillain-Barrésyndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccines: a multinational self-controlled case series in Europe.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33033684" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Antigenic Variability a Potential Factor in Assessing Relationship Between Guillain BarréSyndrome and Influenza Vaccine - Up to Date Literature Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25999283" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Guillain-Barrésyndrome and influenza vaccines: A meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25999283" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Guillain-Barrésyndrome and influenza vaccines: A meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26948435" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Guillain-Barrésyndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26948435" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Guillain-Barrésyndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26948435" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Guillain-Barrésyndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26948435" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Guillain-Barrésyndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34114269" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Guillain-BarréSyndrome Variant Occurring after SARS-CoV-2 Vaccination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34114256" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Guillain-BarréSyndrome following ChAdOx1-S/nCoV-19 Vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34617967" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Association of Receipt of the Ad26.COV2.S COVID-19 Vaccine With Presumptive Guillain-BarréSyndrome, February-July 2021.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36723942" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Reports of Guillain-BarréSyndrome After COVID-19 Vaccination in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35471572" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Incidence of Guillain-BarréSyndrome After COVID-19 Vaccination in the Vaccine Safety Datalink.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35180300" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : COVID-19 vaccination and Guillain-Barrésyndrome: analyses using the National Immunoglobulin Database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37788935" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Risk of Guillain-BarréSyndrome Following COVID-19 Vaccines: A Nationwide Self-Controlled Case Series Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37788935" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Risk of Guillain-BarréSyndrome Following COVID-19 Vaccines: A Nationwide Self-Controlled Case Series Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30143563" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Surgery and risk of Guillain-Barrésyndrome: A French nationwide epidemiologic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1552914" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : The Guillain-Barrésyndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15005776" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Guillain-Barrésyndrome in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16645971" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Guillain-Barréand Miller Fisher syndromes occurring with tumor necrosis factor alpha antagonist therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12352008" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Recent advances in drug-induced neuropathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15217870" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Guillain-Barrésyndrome seen in users of isotretinoin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27468083" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Pembrolizumab-Induced Demyelinating Polyradiculoneuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31653079" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Neurological Immune Related Adverse Events Associated with Nivolumab, Ipilimumab, and Pembrolizumab Therapy-Review of the Literature and Future Outlook.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29443381" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Guillain-Barré-like syndrome during pembrolizumab treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32327451" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Brentuximab vedotin treatment associated with acute and chronic inflammatory demyelinating polyradiculoneuropathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19088488" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : The epidemiology of Guillain-Barrésyndrome worldwide. A systematic literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21422765" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Population incidence of Guillain-Barrésyndrome: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24163275" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Diagnosis of Guillain-Barrésyndrome and validation of Brighton criteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31541214" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Diagnosis and management of Guillain-Barrésyndrome in ten steps.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18443311" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Guillain-Barrésyndrome: incidence and mortality rates in US hospitals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31937584" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Hyper-reflexia in Guillain-Barrésyndrome: systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22143612" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Guillain-Barrésyndrome associated with normal or exaggerated tendon reflexes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9040715" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Pain in Guillain-Barrésyndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20861454" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Pain in Guillain-Barre syndrome: a long-term follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17503142" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Autonomic dysfunction in Guillain-Barrésyndrome and multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31297663" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Dysautonomia in Guillain-BarréSyndrome: Prevalence, Clinical Spectrum, and Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7935521" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Autonomic involvement in Guillain-Barrésyndrome: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28039863" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Prevalence of autonomic dysfunction in hospitalized patients with Guillain-Barrésyndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10522906" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : SIADH as the first symptom of Guillain-Barrésyndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21339497" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Guillain-Barre syndrome and SIADH.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20409715" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Posterior reversible encephalopathy syndrome as a complication of Guillain-Barrésyndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16174951" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Posterior reversible encephalopathy syndrome as the initial manifestation of Guillain-BarréSyndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22318132" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Posterior reversible encephalopathy syndrome as a revealing manifestation of Guillain-Barrésyndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8489203" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Acute motor axonal neuropathy: a frequent cause of acute flaccid paralysis in China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3790970" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : An acute axonal form of Guillain-Barrépolyneuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23042578" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Electrophysiological subtypes and prognosis of Guillain-Barrésyndrome in northeastern China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7600081" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Guillain-Barrésyndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22178332" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Dysfunction of nodes of Ranvier: a mechanism for anti-ganglioside antibody-mediated neuropathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22178332" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Dysfunction of nodes of Ranvier: a mechanism for anti-ganglioside antibody-mediated neuropathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22984203" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Bickerstaff brainstem encephalitis and Fisher syndrome: anti-GQ1b antibody syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6736980" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Neuropathological findings in Miller Fisher syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13334797" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17657801" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Clinical and immunological spectrum of the Miller Fisher syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18678825" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Acute ophthalmoplegia (without ataxia) associated with anti-GQ1b antibody.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28163765" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Pupillary Involvement in Miller Fisher Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8413947" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barrésyndrome: clinical and immunohistochemical studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8437011" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Miller Fisher syndrome is associated with serum antibodies to GQ1b ganglioside.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2819783" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Neuropathy in the Miller Fisher syndrome: clinical and electrophysiologic findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12847079" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Bickerstaff's brainstem encephalitis: clinical features of 62 cases and a subgroup associated with Guillain-Barrésyndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11118247" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Anti-GQ1b IgG antibody syndrome: clinical and immunological range.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11561023" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Bickerstaff's encephalitis and the Miller Fisher syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28888467" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Early electrophysiological findings in Fisher-Bickerstaff syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17923636" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Continuous spectrum of pharyngeal-cervical-brachial variant of Guillain-Barrésyndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2946281" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Unusual clinical variants and signs in Guillain-Barrésyndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8018039" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Further regional variants of acute immune polyneuropathy. Bifacial weakness or sixth nerve paresis with paresthesias, lumbar polyradiculopathy, and ataxia with pharyngeal-cervical-brachial weakness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12138316" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Guillain-barrésyndrome presenting pharyngeal-cervical-brachial weakness in the recovery phase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24808021" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Paraparetic Guillain-Barrésyndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20736188" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Clinicopathological features of acute autonomic and sensory neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9153616" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Treatment of acute pandysautonomia with intravenous immunoglobulin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22431077" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Sensory Guillain-Barrésyndrome and related disorders: an attempt at systematization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9349681" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Prominent sensory ataxia in Guillain-Barrésyndrome associated with IgG anti-GD1b antibody.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19633904" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : A Guillain-Barrésyndrome variant with prominent facial diplegia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26315943" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Isolated facial diplegia in Guillain-Barrésyndrome: Bifacial weakness with paresthesias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26718574" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Acute bulbar palsy as a variant of Guillain-Barrésyndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25023340" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Guillain-Barrésyndrome: pathogenesis, diagnosis, treatment and prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/677829" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Criteria for diagnosis of Guillain-Barrésyndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2194422" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Assessment of current diagnostic criteria for Guillain-Barrésyndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10631631" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : The frequency of clinical variants of Guillain-Barrésyndrome in Ferrara, Italy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10631631" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : The frequency of clinical variants of Guillain-Barrésyndrome in Ferrara, Italy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14975602" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Usefulness of anti-GQ1b IgG antibody testing in Fisher syndrome compared with cerebrospinal fluid examination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25640907" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Cytoalbuminologic dissociation in Asian patients with Guillain-Barréand Miller Fisher syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37076309" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : CSF Findings in Relation to Clinical Characteristics, Subtype, and Disease Course in Patients With Guillain-BarréSyndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9818934" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : Electrophysiological classification of Guillain-Barrésyndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-BarréSyndrome Trial Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11405806" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : Early electrodiagnostic findings in Guillain-Barrésyndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/666277" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : Proximal versus distal slowing of motor nerve conduction velocity in the Guillain-Barrésyndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16758578" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : Sequential electrodiagnostic abnormalities in acute inflammatory demyelinating polyradiculoneuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6261679" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : The physiological basis for symptoms in Guillain-Barrésyndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28968363" id="rid158" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>159 : Guillain-BarréSyndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20855419" id="rid159" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>160 : Conduction block in acute motor axonal neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9065550" id="rid160" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>161 : Patterns of recovery in the Guillain-Barre syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9708542" id="rid161" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>162 : IgG anti-GM1 antibody is associated with reversible conduction failure and axonal degeneration in Guillain-Barrésyndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22010183" id="rid162" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>163 : Antiganglioside antibodies are associated with axonal Guillain-Barrésyndrome: a Japanese-Italian collaborative study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32140865" id="rid163" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>164 : Axonal variants of Guillain-Barrésyndrome: an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20870864" id="rid164" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>165 : Pitfalls in electrodiagnosis of Guillain-Barrésyndrome subtypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27857121" id="rid165" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>166 : Guillain-Barrésyndrome: a century of progress.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19015484" id="rid166" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>167 : GM1/GalNAc-GD1a complex: a target for pure motor Guillain-Barre syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33279873" id="rid167" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>168 : A case of monofocal motor neuropathy with GM1 and GD1b antibodies improved with intravenous immunoglobulin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21427391" id="rid168" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>169 : The relationship between cytomegalovirus infection and Guillain-Barrésyndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31888351" id="rid169" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>170 : Guillain-BarréSyndrome in a Teenage Girl: A Severe Case With Anti-GM2 Antibodies Associated With Acute CMV Infection and Literature Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9646804" id="rid170" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>171 : Guillain-Barrésyndrome: MR imaging findings of the spine in eight patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27067205" id="rid171" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>172 : Magnetic resonance imaging findings in Guillain-Barrésyndrome caused by Zika virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10655769" id="rid172" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>173 : [A case of Miller Fisher syndrome with gadolinium-enhancing lesions in the cranial nerves and the cauda equina on magnetic resonance imaging].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15090361" id="rid173" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>174 : MR imaging findings of spinal posterior column involvement in a case of Miller Fisher syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8960757" id="rid174" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>175 : Cranial nerve enhancement on three-dimensional MRI in Miller Fisher syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25213352" id="rid175" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>176 : Spinal nerve involvement in early Guillain-Barrésyndrome: a clinico-electrophysiological, ultrasonographic and pathological study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25418824" id="rid176" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>177 : Ultrasonography of the peripheral nervous system in the early stage of Guillain-Barrésyndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26228791" id="rid177" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>178 : Serial peripheral nerve ultrasound in Guillain-Barrésyndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30756363" id="rid178" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>179 : Differentiation Between Guillain-BarréSyndrome and Acute-Onset Chronic Inflammatory Demyelinating Polyradiculoneuritis-a Prospective Follow-up Study Using Ultrasound and Neurophysiological Measurements.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20427754" id="rid179" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>180 : Distinguishing acute-onset CIDP from fluctuating Guillain-Barre syndrome: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31399495" id="rid180" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>181 : Acute vestibular syndrome associated with anti-GQ1b antibody.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
